

Day : Monday
Date: 9/23/2002

PALM INTRANET

Time: 08:42:12

Inventor Name Search Result

Your Search was:

Last Name = HORROBIN

First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>06089293</u>	<u>4302447</u>	150	10/30/1979	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06285470</u>	Not Issued	166	07/21/1981	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06783601</u>	Not Issued	166	10/03/1985	COMPOSITIONS OF COPPER AND FATTY ACIDS	HORROBIN , DAVID F.
<u>06798717</u>	Not Issued	166	11/18/1985	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>06804247</u>	Not Issued	166	12/04/1985	TOPICAL PREPARATIONS CONTAINING TAR AND FATTY ACIDS	HORROBIN , DAVID F.
<u>07092191</u>	<u>4855136</u>	150	09/02/1987	THERAPEUTIC COMPOSITION AND METHOD	HORROBIN , DAVID F.
<u>07353248</u>	Not Issued	166	05/12/1989	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>07361699</u>	Not Issued	166	06/02/1989	TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN , DAVID F.
<u>07363334</u>	Not Issued	166	06/08/1989	COMPOSITION AND METHOD FOR TREATMENT OF PEPTIC ULCERS	HORROBIN , DAVID F.
<u>07835072</u>	Not Issued	168	02/18/1992	TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN , DAVID F.
<u>07818501</u>	<u>5145686</u>	150	01/08/1992	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>07611881</u>	Not Issued	166	11/13/1990	DRUG TREATMENTS	HORROBIN , DAVID F.
<u>07598822</u>	Not Issued	161	09/18/1990	COMPOSITION AND METHOD FOR TREATMENT OF PEPTIC ULCERS	HORROBIN , DAVID F.
<u>07598782</u>	Not	166	10/18/1990	ESSENTIAL FATTY ACID	HORROBIN ,

	Issued			COMPOSITION	DAVID F.
<u>07597091</u>	Not Issued	166	10/16/1990	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07593388</u>	Not Issued	161	10/02/1990	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07591604</u>	<u>5120760</u>	150	09/25/1990	TREATING TARDIVE DYSKINESIA WITH ESSENTIAL FATTY ACID COMPOSITIONS	HORROBIN , DAVID F.
<u>07578498</u>	Not Issued	166	09/06/1990	FATTY ACID THERAPY	HORROBIN , DAVID F.
<u>06581671</u>	<u>RE31836</u>	150	02/16/1984	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06575744</u>	<u>4681896</u>	150	01/31/1984	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06559756</u>	Not Issued	161	12/09/1983	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06254113</u>	Not Issued	161	04/14/1981	TREATMENT OF HEART DISEASE	HORROBIN , DAVID F.
<u>06251901</u>	<u>4328243</u>	150	04/07/1981	MANIC-DEPRESSIVE ILLNESSES	HORROBIN , DAVID F.
<u>06038938</u>	<u>4287202</u>	150	05/14/1979	TREATMENT AND/OR PROPHYLAXIS OF SPASMS OF CORONARY ARTERIES	HORROBIN , DAVID F.
<u>08930670</u>	Not Issued	168	11/06/1997	TRIGLYCERIDES	HORROBIN , DAVID F.
<u>08919148</u>	Not Issued	161	08/28/1997	TREATMENT OF VIRAL INFECTIONS	HORROBIN , DAVID F.
<u>08500017</u>	Not Issued	161	07/10/1995	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06846093</u>	Not Issued	161	03/31/1986	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
<u>06839228</u>	<u>4666701</u>	150	03/13/1986	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN , DAVID F.
<u>06833286</u>	Not Issued	166	02/27/1986	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN , DAVID F.
<u>08491244</u>	Not Issued	166	06/16/1995	COMPOSITIONS FOR TREATMENT OF DIABETIC COMPLICATIONS	HORROBIN , DAVID F.
<u>08482446</u>	Not Issued	161	06/07/1995	"PHARMACEUTICAL AND DIETARY COMPOSITION"	HORROBIN , DAVID F.
<u>08285769</u>	Not	166	08/03/1994	PHARMACEUTICAL DIETARY	HORROBIN ,

	Issued			COMPOSITION	DAVID F.
<u>08061110</u>	<u>5380757</u>	150	05/14/1993	METHOD OF TREATING VULVAR DYSTROPHY AND VAGINAL DRYNESS	HORROBIN, DAVID F.
<u>08054344</u>	Not Issued	161	04/29/1993	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.
<u>08051436</u>	<u>5318991</u>	150	04/22/1993	FATTY ACID TREATMENT TO REDUCE CALCIUM EXCRETION	HORROBIN, DAVID F.
<u>07847884</u>	Not Issued	166	03/10/1992	METHOD OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN, DAVID F.
<u>07841770</u>	Not Issued	161	03/02/1992	TREATMENT OF SKIN DISORDERS	HORROBIN, DAVID F.
<u>07363333</u>	Not Issued	161	06/08/1989	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>07359565</u>	<u>4977187</u>	150	06/01/1989	TREATING SCHIZOPHRENIA WITH ESSENTIAL FATTY ACID COMPOSITIONS	HORROBIN, DAVID F.
<u>07117440</u>	Not Issued	166	11/04/1987	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
<u>07089035</u>	Not Issued	161	08/24/1987	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
<u>06798721</u>	Not Issued	166	11/18/1985	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>06786517</u>	Not Issued	166	10/11/1985	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
<u>08930701</u>	<u>5990164</u>	150	03/17/1998	N-ALKYLPOLYHYDROXY AMINE SALTS OF POLYUNSATURATED FATTY ACIDS	HORROBIN, DAVID FREDERICK
<u>09147113</u>	Not Issued	041	04/06/1999	DIAGNOSTIC TEST FOR SCHIZOPHRENIA, USING NIACIN	HORROBIN, DAVID FREDERICK
<u>09376617</u>	<u>6245811</u>	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	HORROBIN, DAVID FREDERICK
<u>06004924</u>	<u>4273763</u>	150	01/19/1979	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID FREDERICK
<u>06029058</u>	<u>4309415</u>	150	04/11/1979	METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS	HORROBIN, DAVID FREDERICK
<u>09155550</u>	Not	041	11/12/1998	POLYETHYLENE GLYCOL	HORROBIN,

[Search and Display More Records.](#)

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="HORROBIN"/>	<input type="text" value="DAVID F"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:42:38

 PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = HORROBIN

First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	HORROBIN , DAVID F
06846093	Not Issued	161	03/31/1986	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
06846094	Not Issued	161	03/31/1986	ANTI-VIRAL COMPOSITIONS	HORROBIN , DAVID F.
07139071	Not Issued	166	12/24/1987	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN , DAVID F.
07147208	4810497	150	01/22/1988	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
07159128	4886670	250	02/23/1988	ANTI-VIRAL COMPOSITIONS	HORROBIN , DAVID F.
07163327	Not Issued	166	03/02/1988	COMPOSITION AND METHOD FOR TREATMENT OF PEPTIC ULCERS	HORROBIN , DAVID F.
07168603	4888326	250	03/04/1988	A METHOD OF TREATING DEFECTIVE T-LYMPHOCYTE FUNCTION WITH RUTIN OR TROXERUTIN IN COMBINATION WITH GAMMA-LINOLENIC ACID OR DIHOMO- GAMMA-LINOLENIC ACID	HORROBIN , DAVID F.
07377817	Not Issued	161	07/06/1989	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN , DAVID F.
07397789	5116871	150	08/24/1989	FATTY ACID THERAPY AND COMPOSITIONS FOR THE TREATMENT OF MYALGIC ENCEPHALOMYELITIS	HORROBIN , DAVID F.
07406526	Not Issued	166	09/13/1989	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.

<u>07620440</u>	Not Issued	166	11/30/1990	METHOD OF ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN, DAVID F.
<u>07628983</u>	Not Issued	166	12/17/1990	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>07628984</u>	Not Issued	161	12/17/1990	TREATMENT OF CEREBRAL DISORDERS	HORROBIN, DAVID F.
<u>07637944</u>	Not Issued	161	01/08/1991	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>07638998</u>	<u>5116624</u>	150	01/09/1991	EFA COMPOSITIONS AND THERAPY	HORROBIN, DAVID F.
<u>07641740</u>	Not Issued	166	01/15/1991	ESSENTIAL FATTY ACID COMPOSITIONS AND TREATMENTS	HORROBIN, DAVID F.
<u>07871761</u>	<u>5246726</u>	150	04/21/1992	IRON-CONTAINING COMPOSITION AND METHOD FOR TREATMENT OF CANCER	HORROBIN, DAVID F.
<u>06899772</u>	Not Issued	166	08/22/1986	PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
<u>06896317</u>	Not Issued	166	08/13/1986	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>06878684</u>	Not Issued	161	06/26/1986	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06642699</u>	<u>4931468</u>	250	08/21/1984	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06640552</u>	Not Issued	166	08/15/1984	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>06632699</u>	Not Issued	166	07/23/1984	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>06630686</u>	Not Issued	166	07/13/1984	FATTY ACID COMPOSITIONS	HORROBIN, DAVID F.
<u>06628270</u>	Not Issued	161	07/06/1984	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
<u>06628268</u>	Not Issued	161	07/06/1984	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.
<u>07892814</u>	Not Issued	166	06/05/1992	FATTY ACID TREATMENT	HORROBIN, DAVID F.
<u>07891037</u>	<u>5328691</u>	250	06/01/1992	FATTY ACID COMPOSITIONS	HORROBIN, DAVID F.
<u>07686285</u>	Not Issued	161	04/16/1991	NUTRITIONAL SUPPLEMENT	HORROBIN, DAVID F.

<u>07670518</u>	Not Issued	166	03/18/1991	TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN , DAVID F.
<u>07668700</u>	Not Issued	166	03/07/1991	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07429601</u>	5080909	150	10/31/1989	ANTI-VIRAL COMPOSITIONS	HORROBIN , DAVID F.
<u>07211057</u>	Not Issued	166	06/24/1988	ESSENTIAL FATTY ACID COMPOSITIONS	HORROBIN , DAVID F.
<u>07182291</u>	Not Issued	161	04/15/1988	LITHIUM SALT-CONTAINING PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06903469</u>	Not Issued	166	09/04/1986	DRUG TREATMENTS	HORROBIN , DAVID F.
<u>09163388</u>	Not Issued	161	09/30/1998	STABILISATION OF POLYUNSATURATES	HORROBIN , DAVID F.
<u>07876908</u>	Not Issued	166	04/30/1992	PHARMACEUTICAL DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>08106989</u>	5618558	150	08/16/1993	FATTY ACID TREATMENT	HORROBIN , DAVID F.
<u>08109482</u>	Not Issued	166	08/20/1993	FATTY ACID TREATMENT	HORROBIN , DAVID F.
<u>08111523</u>	Not Issued	166	08/25/1993	METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN , DAVID F.
<u>08111524</u>	Not Issued	166	08/25/1993	METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN , DAVID F.
<u>08297215</u>	5635189	150	08/29/1994	TOCOPHEROLS	HORROBIN , DAVID F.
<u>08306935</u>	Not Issued	166	09/16/1994	METHOD OF PREVENTING OCCLUSION OF ARTERIES	HORROBIN , DAVID F.
<u>08516687</u>	Not Issued	161	08/18/1995	FATTY ACID THERAPY	HORROBIN , DAVID F.
<u>08531108</u>	Not Issued	168	09/20/1995	FATTY ACID TREATMENT	HORROBIN , DAVID F.
<u>08732454</u>	Not Issued	161	12/13/1996	TUMOUR LOCALISING PHOTSENSITISING COMPOUNDS	HORROBIN , DAVID F.
<u>08944407</u>	Not Issued	161	10/06/1997	METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN , DAVID F.
<u>08945779</u>	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	HORROBIN , DAVID

					FREDERICK
09403754	Not Issued	161	10/29/1999	TREATMENT OF DEPRESSION AND ANXIETY USING DOCOSAHEXAENOIC ACID OR NATURAL ANTIOXIDANTS	HORROBIN , DAVID FREDERICK

[Search and Display More Records.](#)

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="HORROBIN"/>	<input type="text" value="DAVID F"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002


PALM INTRANET

Time: 08:43:06

Inventor Name Search Result

Your Search was:

Last Name = HORROBIN

First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>08365171</u>	5516801	150	12/28/1994	FATTY ACID TREATMENT FOR ECTOPIC CALCIUM DEPOSITION	HORROBIN , DAVID F
<u>07892814</u>	Not Issued	166	06/05/1992	FATTY ACID TREATMENT	HORROBIN , DAVID F.
<u>07912017</u>	Not Issued	168	07/10/1992	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
<u>07912772</u>	Not Issued	166	07/13/1992	PREPARATION OF FATTY ACID MEDICAMENTS	HORROBIN , DAVID F.
<u>08131850</u>	Not Issued	166	10/05/1993	FATTY ACID THERAPY	HORROBIN , DAVID F.
<u>08367819</u>	5580556	150	01/03/1995	PHARMACEUTICAL COMPOSITIONS CONTAINING INTERFERONS AND FATTY ACIDS	HORROBIN , DAVID F.
<u>08555019</u>	Not Issued	166	11/13/1995	FORTIFIED FRUIT JUICE	HORROBIN , DAVID F.
<u>08557545</u>	5859055	150	11/14/1995	METHOD OF PREVENTING OCCLUSION OF ARTERIES	HORROBIN , DAVID F.
<u>08796901</u>	6069168	150	02/06/1997	COMPOSITIONS FOR TREATMENT OF DIABETIC COMPLICATIONS	HORROBIN , DAVID F.
<u>06682829</u>	Not Issued	161	12/19/1984	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06669958</u>	Not Issued	166	11/09/1984	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06653767</u>	Not Issued	166	09/24/1984	TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN , DAVID F.
<u>06650997</u>	Not Issued	166	09/17/1984	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.

<u>06647861</u>	Not Issued	166	09/05/1984	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>06402929</u>	Not Issued	166	07/29/1982	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>06397350</u>	Not Issued	166	07/12/1982	METHOD FOR ENCHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN, DAVID F.
<u>06267657</u>	Not Issued	161	05/27/1981	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06150402</u>	<u>4388324</u>	150	05/15/1980	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>07704603</u>	<u>5178873</u>	150	05/23/1991	ESSENTIAL FATTY ACID TREATMENT	HORROBIN, DAVID F.
<u>07483992</u>	Not Issued	166	02/22/1990	IRON-CONTAINING COMPOSITIONS AND METHOD FOR TREATING CANCER	HORROBIN, DAVID F.
<u>07480375</u>	<u>4996233</u>	150	02/14/1990	A METHOD OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN, DAVID F.
<u>07253397</u>	Not Issued	166	10/04/1988	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
<u>07243235</u>	Not Issued	166	09/09/1988	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>07240276</u>	Not Issued	161	09/06/1988	TREATMENT OF MALE PATTERN BALDNESS AND OF UNWANTED HAIR GROWTH	HORROBIN, DAVID F.
<u>07236442</u>	Not Issued	161	08/25/1988	NUTRITIONAL SUPPLEMENT	HORROBIN, DAVID F.
<u>07235747</u>	Not Issued	166	08/22/1988	TREATMENT OF SKIN DISORDERS	HORROBIN, DAVID F.
<u>07232515</u>	<u>4898885</u>	250	08/15/1988	PHARMACEUTICA AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>08155631</u>	Not Issued	161	11/22/1993	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>07963597</u>	<u>5422115</u>	150	10/20/1992	METHODS OF TREATMENT AND DEVICES EMPLOYING LITHIUM SALTS	HORROBIN, DAVID F.
<u>07959472</u>	<u>5264217</u>	150	10/09/1992	METHOD OF INCREASING THE TOTAL FAT CONTENT OF MILK	HORROBIN, DAVID F.
<u>07956460</u>	<u>5324748</u>	250	10/02/1992	METHOD FOR ENHANCEMENT OF 1-SERIES	HORROBIN, DAVID F.

				PG PRODUCTION	
<u>07936321</u>	Not Issued	166	08/28/1992	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>07732492</u>	<u>5262174</u>	250	07/18/1991	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
<u>07717862</u>	<u>5198468</u>	150	06/19/1991	ESSENTIAL FATTY ACID COMPOSITION	HORROBIN, DAVID F.
<u>07711499</u>	Not Issued	166	05/31/1991	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
<u>07711104</u>	<u>5128152</u>	150	06/03/1991	IRON-CONTAINING COMPOSITIONS AND METHOD FOR TREATING CANCER	HORROBIN, DAVID F.
<u>07217508</u>	Not Issued	166	07/07/1988	TREATMENT OF CEREBRAL DISORDERS	HORROBIN, DAVID F.
<u>06939965</u>	Not Issued	161	12/10/1986	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
<u>06928596</u>	Not Issued	166	11/10/1986	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06925454</u>	Not Issued	166	10/31/1986	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>06921855</u>	Not Issued	161	10/22/1986	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06911794</u>	<u>4826877</u>	150	09/26/1986	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06911719</u>	<u>4758592</u>	150	09/26/1986	METHOD OF TREATING OR PREVENTING ENDOMETRIOSIS	HORROBIN, DAVID F.
<u>06683328</u>	Not Issued	166	12/19/1984	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>08784105</u>	<u>5888541</u>	150	01/15/1997	FATTY ACID TREATMENT	HORROBIN, DAVID F.
<u>08555746</u>	Not Issued	161	11/09/1995	FORTIFIED MILK	HORROBIN, DAVID F.
<u>08543799</u>	<u>5866703</u>	150	10/16/1995	TRIGLYCERIDES	HORROBIN, DAVID F.
<u>08136236</u>	Not Issued	161	10/15/1993	DRUG TREATMENTS	HORROBIN, DAVID F.
<u>08136606</u>	Not Issued	166	10/15/1993	METHOD OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN, DAVID F.
<u>08352460</u>	Not Issued	166	12/09/1994	FATTY ACID COMPOSITION	HORROBIN, DAVID F.

[Search and Display More Records.](#)

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="HORROBIN"/>	<input type="text" value="DAVID F"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002


PALM INTRANET

Time: 08:43:31

Inventor Name Search Result

Your Search was:

Last Name = HORROBIN

First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08155631	Not Issued	161	11/22/1993	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
08158363	Not Issued	166	11/29/1993	PHARMACEUTICAL DIETARY COMPOSITION	HORROBIN , DAVID F.
08158986	5552150	150	11/30/1993	COMPOSITIONS CONTAINING DI-LINOLEOYL-MONO-GAMMA-LINOLENYL-GLYCEROL	HORROBIN , DAVID F.
08178553	5604216	150	01/06/1994	COMPOSITIONS CONTAINING ESTERS OF UNSATURATED FATTY ACIDS	HORROBIN , DAVID F.
08181020	Not Issued	169	01/14/1994	TRIGLYCERIDES	HORROBIN , DAVID F.
08181497	Not Issued	169	01/14/1994	TRIGLYCERIDES	HORROBIN , DAVID F.
08184114	Not Issued	166	01/21/1994	INTERNAL RADIATION DAMAGE	HORROBIN , DAVID F.
08372846	Not Issued	166	01/13/1995	METHODS OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN , DAVID F.
08378708	5508307	150	01/26/1995	METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN , DAVID F.
08392628	5603959	150	02/22/1995	FATTY ACID DERIVATIVES	HORROBIN , DAVID F.
08405431	Not Issued	161	03/16/1995	NUTRITION	HORROBIN , DAVID F.
08584426	5922345	150	01/11/1996	NUTRITION	HORROBIN , DAVID F.
08600004	5614208	150	02/14/1996	METHODS OF TREATMENT USING DI-LINOLEOYL-	HORROBIN , DAVID F.

				MONO-GAMMA-LINOLENYL GLYCEROL	
<u>08600005</u>	<u>5620701</u>	150	02/14/1996	METHODS OF TREATMENT USING DI-LINOLEOYL-MONO-GAMMA-LINOLENYL GLYCEROL	HORROBIN , DAVID F.
<u>08604444</u>	Not Issued	161	02/21/1996	SCHIZOPHRENIA	HORROBIN , DAVID F.
<u>08611525</u>	<u>5589509</u>	150	03/06/1996	METHODS OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN , DAVID F.
<u>08810458</u>	Not Issued	161	03/04/1997	FORTIFIED FRUIT JUICE	HORROBIN , DAVID F.
<u>07009093</u>	Not Issued	166	01/29/1987	METHOD FOR ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN , DAVID F.
<u>07008751</u>	Not Issued	166	01/30/1987	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
<u>07007109</u>	<u>4753964</u>	150	01/27/1987	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06719953</u>	<u>4738853</u>	150	04/04/1985	FOOD PRODUCTION	HORROBIN , DAVID F.
<u>06700065</u>	Not Issued	166	02/11/1985	METHOD FOR ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN , DAVID F.
<u>06458466</u>	Not Issued	161	01/17/1983	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06450037</u>	Not Issued	166	12/15/1982	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06272083</u>	<u>4415554</u>	150	06/10/1981	TREATMENT FOR MENSTRUAL DISORDERS	HORROBIN , DAVID F.
<u>06272081</u>	<u>4444755</u>	150	06/10/1981	TREATMENT FOR SKIN DISORDERS	HORROBIN , DAVID F.
<u>08197741</u>	Not Issued	161	02/17/1994	TREATMENT OF A GROUP OF RELATED DISORDERS	HORROBIN , DAVID F.
<u>08197459</u>	Not Issued	166	02/16/1994	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>08187046</u>	Not Issued	166	01/27/1994	TRIGLYCERIDES	HORROBIN , DAVID F.
<u>08187044</u>	Not Issued	166	01/27/1994	TRIGLYCERIDES	HORROBIN , DAVID F.
<u>08187042</u>	<u>5466841</u>	150	01/27/1994	FORMULATIONS CONTAINING	HORROBIN , DAVID F.

				UNSATURATED FATTY ACIDS	
<u>07990190</u>	<u>5276020</u>	150	12/14/1992	ANTI-VIRALS	HORROBIN , DAVID F.
<u>07981116</u>	<u>5378732</u>	150	11/25/1992	METHOD OF REDUCING THE RATE OF REOCCLUSION OF ARTERIES	HORROBIN , DAVID F.
<u>07765008</u>	<u>5223271</u>	150	09/24/1991	LITHIUM TREATMENT	HORROBIN , DAVID F.
<u>07522085</u>	Not Issued	166	05/11/1990	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>08202981</u>	Not Issued	169	02/28/1994	TREATMENT OF VIRAL INFECTIONS	HORROBIN , DAVID F.
<u>07521075</u>	<u>5216142</u>	150	04/10/1990	ANTI-VIRALS	HORROBIN , DAVID F.
<u>07504037</u>	Not Issued	166	04/04/1990	TREATMENT OF CEREBRAL DISORDERS	HORROBIN , DAVID F.
<u>07280410</u>	<u>4970076</u>	150	12/06/1988	FATTY ACID COMPOSITION	HORROBIN , DAVID F.
<u>07274358</u>	Not Issued	166	11/21/1988	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07273680</u>	<u>4965075</u>	150	11/21/1988	METHOD OF INCREASING 1-SERIES PGS IN THE BODY	HORROBIN , DAVID F.
<u>07045545</u>	<u>4806569</u>	150	05/04/1987	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07042526</u>	Not Issued	166	04/27/1987	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>07028272</u>	Not Issued	166	03/20/1987	IRON-CONTAINING COMPOSITION AND METHOD FOR TREATMENT OF CANCER	HORROBIN , DAVID F.
<u>06069493</u>	<u>4248872</u>	150	08/24/1979	METHOD FOR THE TREATMENT OF ANXIETY	HORROBIN , DAVID F.
<u>09254286</u>	<u>6407075</u>	150	07/06/1999	FATTY ACID TREATMENT	HORROBIN , DAVID F.
<u>08823790</u>	<u>5763484</u>	250	03/24/1997	LIPIDS FOR TREATMENT OF DISEASE	HORROBIN , DAVID F.
<u>08828716</u>	<u>5847000</u>	150	03/28/1997	FATTY ACID DERIVATIVES	HORROBIN , DAVID F.
<u>09034029</u>	<u>6177470</u>	150	03/02/1998	METHODS OF TREATMENT USING ASCORBYL GAMMA LINOLENIC ACID OR ASCORBYL DIHOMO-GAMMA-LINOLENIC ACID	HORROBIN , DAVID F.

<u>09052003</u>	Not Issued	161	03/31/1998	TRIGLYCERIDES	HORROBIN, DAVID F.
-----------------	---------------	-----	------------	---------------	-----------------------

[Search and Display More Records.](#)

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="HORROBIN"/>	<input type="text" value="DAVID F"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002


PALM INTRANET

Time: 08:44:08

Inventor Name Search Result

Your Search was:

Last Name = HORROBIN

First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>08440987</u>	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	HORROBIN , DAVID F
<u>08202981</u>	Not Issued	169	02/28/1994	TREATMENT OF VIRAL INFECTIONS	HORROBIN , DAVID F.
<u>08206399</u>	Not Issued	163	03/07/1994	FATTY ACID TREATMENT	HORROBIN , DAVID F.
<u>08208465</u>	Not Issued	166	03/08/1994	TREATMENT OF VIRAL INFECTIONS	HORROBIN , DAVID F.
<u>08208481</u>	Not Issued	166	03/08/1994	NUTRITION	HORROBIN , DAVID F.
<u>08214553</u>	5562913	150	03/18/1994	FORMULATION FOR USE IN SMOKERS	HORROBIN , DAVID F.
<u>08628692</u>	5871757	150	10/16/1996	STABILISATION OF POLYUNSATURATES	HORROBIN , DAVID F.
<u>08649292</u>	Not Issued	166	05/17/1996	TREATMENT OF VIRAL INFECTIONS	HORROBIN , DAVID F.
<u>06240295</u>	Not Issued	166	03/04/1981	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06487762</u>	Not Issued	166	04/22/1983	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>06476708</u>	4535093	150	03/18/1983	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06469445</u>	Not Issued	166	02/24/1983	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06469444</u>	Not Issued	166	02/24/1983	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>06469443</u>	Not Issued	166	02/24/1983	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>06469442</u>	Not Issued	166	02/24/1983	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>06345214</u>	4386072	150	02/03/1982	TREATMENT OF DISORDERS	HORROBIN ,

				OF INFLAMMATION AND IMMUNITY AND DISORDERS ASSOCIATED WITH SMOOTH MUSCLE SPASM AND COMPOSITIONS THEREOF	DAVID F.
<u>06345204</u>	Not Issued	161	02/03/1982	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06277671</u>	Not Issued	161	06/26/1981	TREATMENT OF DISORDERS OF INFLAMMATION AND IMMUNITY AND DISORDERS ASSOCIATED WITH SMOOTH MUSCLE SPASM	HORROBIN , DAVID F.
<u>07561722</u>	Not Issued	161	08/01/1990	SKIN IMPROVING COMPOSITION AND METHOD	HORROBIN , DAVID F.
<u>07560005</u>	Not Issued	166	07/27/1990	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
<u>07550670</u>	Not Issued	161	07/10/1990	PHARMACEUTICAL AND DIETARY USES OF FATTY ACIDS	HORROBIN , DAVID F.
<u>07536991</u>	Not Issued	166	06/13/1990	TREATMENT OF SKIN DISORDERS	HORROBIN , DAVID F.
<u>07331023</u>	Not Issued	166	03/28/1989	METHOD FOR ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN , DAVID F.
<u>07329881</u>	<u>5252333</u>	150	03/28/1989	LITHIUM SALT-CONTAINING PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>07329277</u>	Not Issued	166	03/27/1989	NUTRITIONAL SUPPLEMENT	HORROBIN , DAVID F.
<u>07321204</u>	<u>4997657</u>	150	03/09/1989	SKIN IMPROVING COMPOSITION AND METHOD	HORROBIN , DAVID F.
<u>07312730</u>	Not Issued	166	02/17/1989	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>08013163</u>	Not Issued	166	02/02/1993	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>08002545</u>	Not Issued	166	01/11/1993	FATTY ACID COMPOSITION	HORROBIN , DAVID F.
<u>07810434</u>	Not Issued	166	12/19/1991	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07803913</u>	Not Issued	166	12/09/1991	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07802644</u>	Not	166	12/09/1991	NUTRITION	HORROBIN ,

	Issued				DAVID F.
<u>07790075</u>	Not Issued	166	11/12/1991	FATTY ACID THERAPY	HORROBIN , DAVID F.
<u>07771800</u>	Not Issued	166	10/07/1991	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
<u>07571012</u>	Not Issued	166	08/22/1990	FATTY ACID COMPOSITION	HORROBIN , DAVID F.
<u>07561992</u>	Not Issued	166	08/02/1990	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>07307952</u>	<u>4868212</u>	150	02/09/1989	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07307945</u>	Not Issued	166	02/09/1989	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>07082914</u>	Not Issued	161	08/10/1987	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>07060857</u>	Not Issued	161	06/12/1987	ANTI-VIRAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06776982</u>	Not Issued	166	09/12/1985	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
<u>06772192</u>	Not Issued	166	09/03/1985	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06763411</u>	Not Issued	166	08/07/1985	TREATMENT OF SKIN DISORDERS	HORROBIN , DAVID F.
<u>06743394</u>	Not Issued	161	06/11/1985	ANTI-VIRAL COMPOSITIONS	HORROBIN , DAVID F.
<u>06240294</u>	Not Issued	161	03/04/1981	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN , DAVID F.
<u>08215963</u>	Not Issued	168	03/18/1994	PREPARATION OF FATTY ACID MEDICAMENTS	HORROBIN , DAVID F.
<u>08408135</u>	<u>5583159</u>	150	03/21/1995	TREATMENT OF INTERNAL RADIATION DAMAGE	HORROBIN , DAVID F.
<u>08416529</u>	Not Issued	166	04/03/1995	METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN , DAVID F.
<u>08416930</u>	Not Issued	168	04/04/1995	PHARMACEUTICAL DIETARY COMPOSITION	HORROBIN , DAVID F.
<u>08422614</u>	<u>5594031</u>	150	04/13/1995	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.

[Search and Display More Records.](#)

Last Name

First Name

Search Another: Inventor

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:44:22

 **PALM INTRANET**

Inventor Name Search Result

Your Search was:

Last Name = HORROBIN

First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08013163	Not Issued	166	02/02/1993	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
08015035	Not Issued	166	02/08/1993	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
08462557	Not Issued	161	06/05/1995	FATTY ACID COMPOSITION	HORROBIN , DAVID F.
09093775	Not Issued	168	06/09/1998	TUMOUR LOCALISING PHOTSENSITISING COMPOUNDS	HORROBIN , DAVID F.

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name	First Name	
<input type="text" value="HORROBIN"/>	<input type="text" value="DAVID F"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002


PALM INTRANET

Time: 08:44:48

Inventor Name Search Result

Your Search was:

Last Name = MANKU

First Name = MEHAR

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>09376617</u>	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	MANKU , MEHAR
<u>08945667</u>	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	MANKU , MEHAR
<u>08945779</u>	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	MANKU , MEHAR
<u>08952305</u>	6015821	150	03/03/1998	NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	MANKU , MEHAR
<u>08440987</u>	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	MANKU , MEHAR S
<u>06783601</u>	Not Issued	166	10/03/1985	COMPOSITIONS OF COPPER AND FATTY ACIDS	MANKU , MEHAR S.
<u>06839228</u>	4666701	150	03/13/1986	PHARMACEUTICAL AND DIETARY COMPOSITIONS	MANKU , MEHAR S.
<u>08543799</u>	5866703	150	10/16/1995	TRIGLYCERIDES	MANKU , MEHAR S.
<u>08828716</u>	5847000	150	03/28/1997	FATTY ACID DERIVATIVES	MANKU , MEHAR S.
<u>07273680</u>	4965075	150	11/21/1988	METHOD OF INCREASING 1-SERIES PGS IN THE BODY	MANKU , MEHAR S.
<u>08187046</u>	Not Issued	166	01/27/1994	TRIGLYCERIDES	MANKU , MEHAR S.
<u>08187044</u>	Not Issued	166	01/27/1994	TRIGLYCERIDES	MANKU , MEHAR S.
<u>08187042</u>	5466841	150	01/27/1994	FORMULATIONS CONTAINING UNSATURATED FATTY ACIDS	MANKU , MEHAR S.
<u>08388667</u>	Not Issued	166	02/17/1995	FATTY ACID DERIVATIVES	MANKU , MEHAR S.

<u>08930670</u>	Not Issued	168	11/06/1997	TRIGLYCERIDES	MANKU , MEHAR S.
<u>08297215</u>	5635189	150	08/29/1994	TOCOPHEROLS	MANKU , MEHAR S.
<u>09155550</u>	Not Issued	041	11/12/1998	POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS	MANKU , MEHAR SINGH
<u>09052003</u>	Not Issued	161	03/31/1998	TRIGLYCERIDES	MANKU , MEHAR SINGH
<u>09034029</u>	6177470	150	03/02/1998	METHODS OF TREATMENT USING ASCORBYL GAMMA LINOLENIC ACID OR ASCORBYL DIHOMO-GAMMA- LINOLENIC ACID	MANKU, MEHAR S.
<u>09424194</u>	Not Issued	161	02/24/2000	GLUCOSAMINE FATTY ACID COMPOSITIONS AND THEIR USE	MANKU, MEHAR SINGH

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="MANKU"/>	<input type="text" value="MEHAR"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:45:15

 PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = PITT

First Name = ANDREA

Application#	Patent#	Status	Date Filed	Title	Inventor Name
09376617	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	PITT , ANDREA
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	PITT , ANDREA
08945779	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	PITT , ANDREA
08952305	6015821	150	03/03/1998	NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	PITT , ANDREA
06789326	4697798	150	10/21/1985	APPARATUS FOR LIFTING EQUIPMENT	PITTER , ANDREAS
06586604	Not Issued	161	03/06/1984	PROCEDURE FOR OPTIMIZING THE REGULATION OF ELECTRODES IN AN ARC FURNACE, AND DEVICE WHICH CARRIES OUT THE PROCEDURE	PITTINI , ANDREA
06587726	4644559	250	03/08/1984	PROCEDURE FOR CONTROLLING THE TYPE OF ARC IN AN ELECTRICAL FURNACE, AND ARC FURNACE WHICH EMPLOYS THE PROCEDURE	PITTINI , ANDREA
06206699	Not Issued	161	11/14/1980	COOLING PANEL FOR ELECTRIC ARC FURNACES	PITTINI , ANDREA

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name	First Name
<input type="text" value="PITT"/>	<input type="text" value="ANDREA"/>
<input type="button" value="Search"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002


PALM INTRANET

Time: 08:46:38

Inventor Name Search Result

Your Search was:

Last Name = BRADLEY

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	BRADLEY , PAUL
07658395	Not Issued	161	02/20/1991	PHOTOLITHOGRAPHIC PATTERNING OF THIN FILMS	BRADLEY , PAUL
07666397	D326261	150	03/08/1991	TRACKBALL FOR COMPUTER	BRADLEY , PAUL
07665840	D342241	150	03/08/1991	COMPUTER TRACKBALL	BRADLEY , PAUL
07159039	4972042	150	02/12/1988	BLOCKING ARRANGEMENT FOR SUPPRESSING FLUID TRANSMISSION IN CABLES	BRADLEY , PAUL A.
07445541	Not Issued	161	12/04/1989	PACKET FILTER FOR BRIDGE BETWEEN NETWORKS	BRADLEY , PAUL A.
09380375	6201004	150	09/01/1999	DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	BRADLEY , PAUL ANTHONY
08110389	5400026	150	08/23/1993	FLASH ANALOG-TO-DIGITAL CONVERTER EMPLOYING JOSEPHSON JUNCTIONS	BRADLEY , PAUL D.
07658396	Not Issued	164	02/20/1991	NON DESTRUCTIVE READ-OUT MEMORY CELL AND MEMORY ARRAY WITH A SENSE JOSEPHSON JUNCTION	BRADLEY , PAUL D.
07658404	Not Issued	161	02/20/1991	MEMORY EMPLOYING JOSEPHSON JUNCTIONS	BRADLEY , PAUL D.
09193809	5951141	150	11/17/1998	HEAD MOUNTED ILLUMINATION DEVICE	BRADLEY , PAUL DAVID
07091783	D302426	150	09/01/1987	COMPUTER MOUSE	BRADLEY , PAUL E.
08925831	6005553	150	09/05/1997	ERGONOMIC COMPUTER	BRADLEY , PAUL

				MOUSE	E.
<u>08129811</u>	<u>5438475</u>	150	09/30/1993	PORTABLE COMPUTER WITH AN ELECTRONIC PEN STORAGE TURRET	BRADLEY, PAUL E.
<u>09352668</u>	Not Issued	120	07/09/1999	ERGONOMIC COMPUTER MOUSE MAT	BRADLEY, PAUL E.
<u>60086410</u>	Not Issued	159	05/22/1998	SCALABLE SYSTEM FOR CLUSTERING OF LARGE DATABASES HAVING MIXED DATA ATTRIBUTES	BRADLEY, PAUL S.
<u>06025281</u>	<u>4239308</u>	150	03/29/1979	DISPLAY TRAY ASSEMBLY	BRADLEY, PAUL W.
<u>09841234</u>	Not Issued	094	04/23/2001	CONTROLLED EFFECTIVE COUPLING COEFFICIENTS FOR FILM BULK ACOUSTIC RESONATORS	BRADLEY, PAUL
<u>09906581</u>	Not Issued	041	07/13/2001	THIN FILM BULK ACOUSTIC RESONATOR (FBAR) AND INDUCTOR ON A MONOLITHIC SUBSTRATE AND METHOD OF FABRICATING THE SAME	BRADLEY, PAUL
<u>60301917</u>	Not Issued	020	06/29/2001	INTERFACE FOR GENERATING AND PRESENTING ITEM RECOMMENDATIONS	BRADLEY, PAUL
<u>29134965</u>	<u>D452226</u>	150	01/03/2001	DIGITAL AUDIO PLAYER	BRADLEY, PAUL
<u>09702499</u>	Not Issued	061	10/31/2000	PACKAGING METHODOLOGY FOR DUPLEXERS USING FBARS	BRADLEY, PAUL
<u>29148377</u>	Not Issued	095	09/19/2001	MP3 AUDIO PLAYER	BRADLEY, PAUL
<u>29134957</u>	<u>D458241</u>	150	01/03/2001	DIGITAL AUDIO PLAYER CHARGING STATION	BRADLEY, PAUL
<u>09733704</u>	Not Issued	093	12/09/2000	MOUNTING FILM BULK ACOUSTIC RESONATORS IN MICROWAVE PACKAGES USING FLIP CHIP BONDING TECHNOLOGY	BRADLEY, PAUL
<u>29135779</u>	Not Issued	093	01/19/2001	MOVEABLE CABINET WITH COMPUTER DISPLAY	BRADLEY, PAUL
<u>10044613</u>	Not Issued	030	01/11/2002	REMOVABLE CUSTOMIZABLE INSERTS AND FACEPLATE FOR	BRADLEY, PAUL

				ELECTRONIC DEVICES	
<u>09798496</u>	Not Issued	030	03/01/2001	METHOD OF FABRICATING THIN FILM BULK ACOUSTIC RESONATOR (FBAR) AND FBAR STRUCTURE EMBODYING THE METHOD	BRADLEY, PAUL
<u>09783773</u>	<u>6462631</u>	150	02/14/2001	PASSBAND FILTER HAVING AN ASYMMETRICAL FILTER RESPONSE	BRADLEY, PAUL
<u>09748153</u>	<u>6353002</u>	150	12/27/2000	THERAPEUTIC AGENTS	BRADLEY, PAUL ANTHONY
<u>09746525</u>	<u>6424237</u>	150	12/21/2000	BULK ACOUSTIC RESONATOR PERIMETER REFLECTION SYSTEM	BRADLEY, PAUL D.
<u>09799149</u>	Not Issued	094	03/05/2001	METHOD OF PROVIDING DIFFERENTIAL FREQUENCY ADJUSTS IN A THIN FILM BULK ACOUSTIC RESONATOR (FBAR) FILTER AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
<u>10209579</u>	Not Issued	020	07/30/2002	RESONATOR WITH PROTECTIVE LAYER	BRADLEY, PAUL D.
<u>10209602</u>	Not Issued	020	07/30/2002	ELECTROSTATIC DISCHARGE PROTECTION ON THIN-FILM RESONATORS	BRADLEY, PAUL D.
<u>10209624</u>	Not Issued	020	07/30/2002	RESONATOR WITH SEED LAYER	BRADLEY, PAUL D.
<u>09799148</u>	Not Issued	041	03/05/2001	METHOD FOR MAKING THIN FILM BULK ACOUSTIC RESONATORS (FBARS) WITH DIFFERENT FREQUENCIES ON A SINGLE SUBSTRATE AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
<u>09799153</u>	Not Issued	061	03/05/2001	METHOD OF PROVIDING DIFFERENTIAL FREQUENCY ADJUSTS IN A THIN FILM BULK ACOUSTIC RESONATOR (FBAR) FILTER AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
<u>09799202</u>	Not Issued	030	03/05/2001	METHOD FOR PRODUCING THIN FILM BULK ACOUSTIC RESONATORS (FBARS) WITH DIFFERENT FREQUENCIES ON	BRADLEY, PAUL D.

				THE SAME SUBSTRATE BY SUBTRACTING METHOD AND APPARATUS EMBODYING THE METHOD	
<u>09799204</u>	Not Issued	095	03/05/2001	METHOD OF MASS LOADING OF THIN FILM BULK ACOUSTIC RESONATORS (FBAR) FOR CREATING RESONATORS OF DIFFERENT FREQUENCIES AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
<u>09799205</u>	Not Issued	041	03/05/2001	METHOD FOR PRODUCING THIN FILM BULK ACOUSTIC RESONATORS (FBARS) WITH DIFFERENT FREQUENCIES ON THE SAME SUBSTRATE BY SUBTRACTING METHOD AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
<u>29126514</u>	<u>D451916</u>	150	07/13/2000	FACE OF TERMINAL APPARATUS	BRADLEY, PAUL EUGENE
<u>09462697</u>	<u>6436323</u>	150	02/09/2000	PRODUCTION OF FIBRE	BRADLEY, PAUL JONATHAN
<u>09607365</u>	<u>6449612</u>	150	06/30/2000	VARYING CLUSTER NUMBER IN A SCALABLE CLUSTERING SYSTEM FOR USE WITH LARGE DATABASES	BRADLEY, PAUL S.
<u>09500172</u>	Not Issued	093	02/08/2000	ITERATIVE VALIDATION AND SAMPLING-BASED CLUSTERING USING ERROR-TOLERANT FREQUENT ITEM SETS	BRADLEY, PAUL S.
<u>09500265</u>	Not Issued	041	02/08/2000	RETROFITTING RECOMMENDER SYSTEMS	BRADLEY, PAUL S.
<u>09845151</u>	Not Issued	030	04/30/2001	APPARATUS AND ACCOMPANYING METHODS FOR VISUALIZING CLUSTERS OF DATA AND HIERARCHICAL CLUSTER CLASSIFICATIONS	BRADLEY, PAUL S.
<u>09700606</u>	Not Issued	030	01/31/2001	SCALABLE SYSTEM FOR CLUSTERING OF LARGE DATABASES HAVING MIXED DATA ATTRIBUTES	BRADLEY, PAUL S.
<u>09876321</u>	Not Issued	030	06/07/2001	METHOD OF REDUCING DIMENSIONALITY OF A SET	BRADLEY, PAUL S.

				OF ATTRIBUTES USED TO CHARACTERIZE A SPARSE DATA SET	
09886771	Not Issued	019	06/21/2001	CLUSTERING OF DATABASES HAVING MIXED DATA ATTRIBUTES	BRADLEY, PAUL S.
09500173	Not Issued	030	02/08/2000	DATA CLUSTERING USING ERROR-TOLERANT FREQUENT ITEM SETS	BRADLEY, PAUL S.

[Search and Display More Records.](#)

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="BRADLEY"/>	<input type="text" value="PAUL"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:46:52


PALM INTRANET

Inventor Name Search Result

Your Search was:

Last Name = BRADLEY

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
07718151	D348057	150	06/13/1991	COMPUTER MOUSE	BRADLEY , PAUL
07731626	5281958	150	07/17/1991	POINTING DEVICE WITH ADJUSTABLE CLAMP ATTACHABLE TO A KEYBOARD	BRADLEY , PAUL
29002935	D347628	150	12/23/1992	COMPUTER TRACKBALL	BRADLEY , PAUL
08176428	Not Issued	161	12/30/1993	POINTING DEVICE WITH ADJUSTABLE CLAMP ATTACHABLE TO A KEYBOARD	BRADLEY , PAUL
29002937	D353370	150	03/05/1993	COMPUTER TRACKBALL	BRADLEY , PAUL
07528173	Not Issued	164	05/24/1990	RETRACTABLE ELECTRICAL EXTENSION CABLE	BRADLEY , PAUL
09282082	6215375	150	03/30/1999	BULK ACOUSTIC WAVE RESONATOR WITH IMPROVED LATERAL MODE SUPPRESSION	BRADLEY , PAUL
29071913	D395894	150	05/30/1997	MICROPHONE	BRADLEY , PAUL
29071912	D395893	150	05/30/1997	MICROPHONE	BRADLEY , PAUL
07280997	D311737	150	12/07/1988	REMOVABLE HARD DISK DRIVE MODULE	BRADLEY , PAUL
08564155	5741800	150	12/21/1995	AZOLYL-CYCLIC AMINE DERIVATES WITH IMMUNOMODULATORY ACTIVITY	BRADLEY , PAUL A.
08809354	Not Issued	161	03/14/1997	SEALING MEMBER	BRADLEY , PAUL A.
09091129	6107310	150	06/16/1998	HETEROARYLCARBOXAMIDE	BRADLEY ,

				DERIVATIVES FOR TREATING CNS DISORDERS	PAUL ANTHONY
<u>09331064</u>	<u>6218405</u>	150	06/16/1999	HETEROARYLSULFONAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	BRADLEY , PAUL ANTHONY
<u>09324618</u>	<u>6262637</u>	150	06/02/1999	DUPLEXER INCORPORATING THIN-FILM BULK ACOUSTIC RESONATORS (FBARS)	BRADLEY , PAUL D.
<u>29052173</u>	<u>D386756</u>	150	03/25/1996	COMPUTER KEYBOARD	BRADLEY , PAUL E
<u>08129811</u>	<u>5438475</u>	150	09/30/1993	PORTABLE COMPUTER WITH AN ELECTRONIC PEN STORAGE TURRET	BRADLEY , PAUL E.
<u>29011532</u>	<u>D355901</u>	150	08/06/1993	COMPUTER MOUSE	BRADLEY , PAUL E.
<u>29087267</u>	<u>D422262</u>	150	04/29/1998	HOUSING FOR PIGGYBACK MOUNTED BATTERY FOR PORTABLE PHONE	BRADLEY , PAUL E.
<u>29087266</u>	<u>D413857</u>	150	04/29/1998	HOUSING FOR PIGGYBACK MOUNTED BATTERY FOR PORTABLE PHONE	BRADLEY , PAUL E.
<u>29072206</u>	<u>D399835</u>	150	05/30/1997	ERGONOMIC COMPUTER MOUSE	BRADLEY , PAUL E.
<u>29056351</u>	<u>D382265</u>	150	06/27/1996	SPEAKERPHONE	BRADLEY , PAUL E.
<u>29021001</u>	<u>D362249</u>	150	03/08/1994	PORTABLE TELEPHONE	BRADLEY , PAUL E.
<u>29011371</u>	Not Issued	169	07/29/1993	PORTABLE TELEPHONE	BRADLEY , PAUL E.
<u>08129835</u>	Not Issued	161	09/30/1993	PORTABLE COMPUTER DISPLAY MOUNTING APPARATUS	BRADLEY , PAUL E.
<u>08153254</u>	Not Issued	161	11/16/1993	PORTABLE COMPUTER DISPLAY MOUNTING DEVICE	BRADLEY , PAUL E.
<u>60163557</u>	Not Issued	159	11/05/1999	CAMERA	BRADLEY , PAUL EUGEN
<u>60163555</u>	Not Issued	159	11/05/1999	STRAP FOR CAMERA AND LENS- FITTED PHOTO FILM UNIT	BRADLEY , PAUL EUGENE
<u>60163562</u>	Not Issued	159	11/05/1999	OBJECT BRIGHTNESS INDICATOR	BRADLEY , PAUL EUGENE
<u>60163556</u>	Not Issued	159	11/05/1999	WRAPPING CASE FOR LENS- FITTED PHOTO FILM UNIT	BRADLEY , PAUL EUGENE
<u>29111091</u>	<u>D433679</u>	150	09/22/1999	TERMINAL APPARATUS	BRADLEY ,

					PAUL EUGENE
<u>07520289</u>	<u>5042405</u>	150	05/07/1990	YARN CONTROL METHOD AND APPARATUS	BRADLEY , PAUL J.
<u>08642490</u>	<u>5782256</u>	250	05/03/1996	CONTOURED FOOT FOR AMBULATORY AID	BRADLEY , PAUL M.
<u>09034834</u>	<u>6115708</u>	150	03/04/1998	METHOD FOR REFINING THE INITIAL CONDITIONS FOR CLUSTERING WITH APPLICATIONS TO SMALL AND LARGE DATABASE CLUSTERING	BRADLEY , PAUL S.
<u>09083906</u>	<u>6263337</u>	150	05/22/1998	A SCALABLE SYSTEM FOR EXPECTATION MAXIMIZATION CLUSTERING OF LARGE DATABASES	BRADLEY , PAUL S.
<u>09034959</u>	Not Issued	169	03/04/1998	METHOD FOR REFINING THE INITIAL CONDITIONS FOR CLUSTERING WITH APPLICATIONS TO SMALL AND LARGE DATABASE CLUSTERING	BRADLEY , PAUL S.
<u>09040219</u>	<u>6374251</u>	150	03/17/1998	SCALABLE SYSTEM FOR CLUSTERING OF LARGE DATABASES	BRADLEY , PAUL S.
<u>09042540</u>	<u>6012058</u>	150	03/17/1998	SCALABLE SYSTEM FOR K-MEANS CLUSTERING OF LARGE DATABASES	BRADLEY , PAUL S.

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="BRADLEY"/>	<input type="text" value="PAUL"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:47:08

PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = WAKEFIELD

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	WAKEFIELD , PAUL
08109830	5535261	150	08/20/1993	SELECTIVELY ACTIVATED INTEGRATED REAL-TIME RECORDING OF TELEPHONE CONVERSATIONS	WAKEFIELD , PAUL A. J.
08226665	5485507	150	04/12/1994	INTEGRATED COMMISSARY SYSTEM	WAKEFIELD , PAUL A. J.
09155550	Not Issued	041	11/12/1998	POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS	WAKEFIELD , PAUL ANDREW
09027576	Not Issued	161	02/23/1998	ENCODING A PORTION OF A DIGITAL IMAGE	WAKEFIELD , PAUL DAVID

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="WAKEFIELD"/>	<input type="text" value="PAUL"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:44:54


PALM INTRANET

Inventor Name Search Result

Your Search was:

Last Name = MCMORDIE

First Name = AUSTIN

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08930670	Not Issued	168	11/06/1997	TRIGLYCERIDES	MCMORDIE , AUSTIN
09376617	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	MCMORDIE , AUSTIN
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	MCMORDIE , AUSTIN
08952305	6015821	150	03/03/1998	NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	MCMORDIE , AUSTIN
09052003	Not Issued	161	03/31/1998	TRIGLYCERIDES	MCMORDIE , AUSTIN
08187044	Not Issued	166	01/27/1994	TRIGLYCERIDES	MCMORDIE , AUSTIN
08440987	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	MCMORDIE , AUSTIN
08187046	Not Issued	166	01/27/1994	TRIGLYCERIDES	MCMORDIE , AUSTIN
08187042	5466841	150	01/27/1994	FORMULATIONS CONTAINING UNSATURATED FATTY ACIDS	MCMORDIE , AUSTIN
08543799	5866703	150	10/16/1995	TRIGLYCERIDES	MCMORDIE , AUSTIN
08945779	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	MCMORDIE , AUSTIN
09424194	Not Issued	161	02/24/2000	GLUCOSAMINE FATTY ACID COMPOSITIONS AND THEIR USE	MCMORDIE, AUSTIN

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="MCMORDIE"/>	<input type="text" value="AUSTIN"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002


PALM INTRANET

Time: 08:44:57

Inventor Name Search Result

Your Search was:

Last Name = KNOWLES

First Name = PHILIP

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>08930701</u>	5990164	150	03/17/1998	N-ALKYLPOLYHYDROXY AMINE SALTS OF POLYUNSATURATED FATTY ACIDS	KNOWLES , PHILIP
<u>09155550</u>	Not Issued	041	11/12/1998	POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS	KNOWLES , PHILIP
<u>09376617</u>	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	KNOWLES , PHILIP
<u>06044511</u>	4442115	150	06/01/1979	2, HYDROXY TETRAZOLE -5- CARBOXANILIDES AND ANTI-ALLERG, USE THEREOF	KNOWLES , PHILIP
<u>06587969</u>	Not Issued	166	03/09/1984	AMINOETHENES	KNOWLES , PHILIP
<u>08945667</u>	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	KNOWLES , PHILIP
<u>08945779</u>	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	KNOWLES , PHILIP
<u>08952305</u>	6015821	150	03/03/1998	NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	KNOWLES , PHILIP
<u>08543799</u>	5866703	150	10/16/1995	TRIGLYCERIDES	KNOWLES , PHILIP
<u>08181020</u>	Not Issued	169	01/14/1994	TRIGLYCERIDES	KNOWLES , PHILIP
<u>08388667</u>	Not Issued	166	02/17/1995	FATTY ACID DERIVATIVES	KNOWLES , PHILIP
<u>08392628</u>	5603959	150	02/22/1995	FATTY ACID DERIVATIVES	KNOWLES , PHILIP

08828716	5847000	150	03/28/1997	FATTY ACID DERIVATIVES	KNOWLES , PHILIP
09034029	6177470	150	03/02/1998	METHODS OF TREATMENT USING ASCORBYL GAMMA LINOLENIC ACID OR ASCORBYL DIHOMO-GAMMA- LINOLENIC ACID	KNOWLES , PHILIP
09052003	Not Issued	161	03/31/1998	TRIGLYCERIDES	KNOWLES , PHILIP
06198490	Not Issued	161	10/20/1982	BENZAMIDE DERIVATIVES	KNOWLES , PHILIP
06707528	Not Issued	166	03/04/1985	AMINOETHENES	KNOWLES , PHILIP
08187044	Not Issued	166	01/27/1994	TRIGLYCERIDES	KNOWLES , PHILIP
08187046	Not Issued	166	01/27/1994	TRIGLYCERIDES	KNOWLES , PHILIP
08440987	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	KNOWLES , PHILIP
06777866	4647569	150	09/19/1985	ANTIARTHRITIC PYRIDYLAMINETHENE DISULFONYL COMPOUNDS AND USE	KNOWLES , PHILIP

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="KNOWLES"/>	<input type="text" value="PHILIP"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Monday
Date: 9/23/2002

Time: 08:45:10

PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = REDDEN

First Name = PETER

Application#	Patent#	Status	Date Filed	Title	Inventor Name
09376617	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	REDDEN , PETER
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	REDDEN , PETER
08945779	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	REDDEN , PETER
08952305	6015821	150	03/03/1998	NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	REDDEN , PETER
07036244	Not Issued	161	04/09/1987	INFLATABLE SPORTS LUGGAGE BAG	REDDEN , PETER
60270198	Not Issued	020	02/22/2001	DIBENZO[C]CHROMEN-6-ONE DERIVATIVES AS ANTI-CANCER AGENTS	REDDEN, PETER
09934086	Not Issued	041	08/21/2001	DIBENZO[C]CHROMEN-6-ONE DERIVATIVES AS ANTI-CANCER AGENTS	REDDEN, PETER

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name	First Name	Search
<input type="text" value="REDDEN"/>	<input type="text" value="PETER"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:48:37 ON 23 SEP 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:48:44 ON 23 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2

DICTIONARY FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s adrenic acid

1 ADRENIC

5576167 ACID

7845 ACIDS

5581876 ACID

(ACID OR ACIDS)

L1

1 ADRENIC ACID

(ADRENIC(W)ACID)

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 2091-25-0 REGISTRY
CN 7,10,13,16-Docosatetraenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Adrenic acid
FS 3D CONCORD
MF C22 H36 O2
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECTNO, CA, CAOLD, CAPLUS, CASREACT, CSCHM, DDFU, DRUGU, EMBASE,
MEDLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

PAGE 1-A

$\text{HO}_2\text{C}-(\text{CH}_2)_5-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-$

PAGE 1-B

$-(\text{CH}_2)_4-\text{Me}$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


159 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
159 REFERENCES IN FILE CAPLUS (1962 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s parinaric acid
10 PARINARIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
L2 9 PARINARIC ACID
(PARINARIC(W)ACID)

=> d scan

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, methyl ester, (2Z,2E,E)- (8CI, 9CI)
MF C19 H30 O2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI)
MF C18 H28 O2
CI COM


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, (9E,11E,13E,15E)- (9CI)
MF C18 H28 O2
CI COM



Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cholest-5-en-3-ol (3.beta.)-, 9,11,13,15-octadecatetraenoate (9CI)
MF C45 H72 O2

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI)
 MF C18 H28 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 9,11,13,15-Octadecatetraenoic acid, anhydride (9CI)
 MF C36 H54 O3

PAGE 1-A




PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 9,11,13,15-Octadecatetraenoic acid, methyl ester (7CI, 8CI, 9CI)
 MF C19 H30 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Cholest-5-en-3-ol (3.beta.)-, (9Z,11E,13E,15Z)-9,11,13,15-octadecatetraenoate (9CI)
 MF C45 H72 O2

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, methyl ester, (all-E)- (9CI)
MF C19 H30 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


ALL ANSWERS HAVE BEEN SCANNED

```
=> s gamma linolenic acid
    112172 GAMMA
        1 GAMMAS
    112172 GAMMA
        (GAMMA OR GAMMAS)
        122 LINOENIC
    5576167 ACID
        7845 ACIDS
    5581876 ACID
        (ACID OR ACIDS)
L3      14 GAMMA LINOENIC ACID
        (GAMMA(W) LINOENIC (W) ACID)

=> d scan
```

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 8,11,13-Eicosatrienoic acid, 15-hydroxy-, (8Z,11Z,13E)- (9CI)
 MF C20 H34 O3

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, methyl ester, (6Z,9Z,12Z)- (9CI)
 MF C19 H32 O2


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 8,11,14-Eicosatrienoic acid, methyl ester, (8Z,11Z,14Z)- (9CI)
 MF C21 H36 O2


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, ethyl ester, (6Z,9Z,12Z)- (9CI)
 MF C20 H34 O2
 CI COM


Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, 1,2,3-propanetriyl ester,
 (6Z,9'Z,12'Z,9Z,9'Z,12Z,12'Z,12'Z)- (9CI)
 MF C57 H92 O6

Double bond geometry as shown.




PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 8,11,14-Eicosatrienoic acid, sodium salt, (Z,Z,Z)- (9CI)
 MF C20 H34 O2 . Na


Double bond geometry as shown.



● Na

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 11,14-Eicosadienoic acid, methyl ester, (11Z,14Z)- (9CI)
 MF C21 H38 O2


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, zinc salt, (Z,Z,Z)- (9CI)
 MF C18 H30 O2 . 1/2 Zn


Double bond geometry as shown.



● 1/2 Zn

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, sodium salt, (Z,Z,Z)- (9CI)
 MF C18 H30 O2 . Na

Double bond geometry as shown.




● Na

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Vincalukoblastine, 22-oxo-, mixt. with (Z,Z,Z)-6,9,12-octadecatrienoic acid (9CI)
 MF C46 H56 N4 O10 . C18 H30 O2
 CI MXS


CH 1

Double bond geometry as shown.



CH 2


Absolute stereochemistry.




L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, monoester with 1,2,3-propanetriol, (Z,Z,Z)- (9CI)
 MF C21 H36 O4
 CI IDS

CH 1

Double bond geometry as shown.



CH 2




L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-, mixt. with sulfur (9CI)
 MF C18 H30 O2 . S
 CI MXS

CH 1

S


CH 2

Double bond geometry as shown.



L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI)
 MF C18 H30 O2
 CI COM


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI)
 MF C20 H34 O2
 CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED


=> s di homo gamma linolenic acid

519 DIHOMO
112172 GAMMA
1 GAMMAS
112172 GAMMA
(GAMMA OR GAMMAS)
122 LINOLENIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
L4 4 DIHOMO GAMMA LINOLENIC ACID
(DIHOMO (W) GAMMA (W) LINOLENIC (W) ACID)

=> d scan

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14-Eicosatrienoic acid, methyl ester, (8Z,11Z,14Z)- (9CI)
MF C21 H36 O2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14-Eicosatrienoic acid, sodium salt, (Z,Z,Z)- (9CI)
MF C20 H34 O2 . Na


Double bond geometry as shown.



● Na

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI)
MF C20 H34 O2
CI COM


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,13-Eicosatrienoic acid, 15-hydroxy-, (8Z,11Z,13E)- (9CI)
MF C20 H34 O3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


ALL ANSWERS HAVE BEEN SCANNED

=> s arachidonic acid
77 ARACHIDONIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
L5 73 ARACHIDONIC ACID
(ARACHIDONIC (W) ACID)

=> d scan

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14-Eicosatetraeneperoxoic acid, (all-Z)- (9CI)
 MF C20 H32 O3

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9


L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14-Eicosatetraenoic acid, hydroxy-, (5Z,8Z,11Z,14Z)- (9CI)
 MF C20 H32 O3
 CI IDS

PAGE 1-A




D1-OH

PAGE 1-B



L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14-Eicosatetraenoic acid, 2,2-dimethyl-, (5Z,8Z,11Z,14Z)- (9CI)
 MF C22 H36 O2


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14-Eicosatetraenoic acid, 19-oxo-, (all-Z)- (9CI)
 MF C20 H30 O3


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11-Eicosatrien-14-ynoic acid, (Z,Z,Z)- (9CI)
 MF C20 H30 O2

Double bond geometry as shown.



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14-Eicosatetraenoic acid, labeled with carbon-14, (all-Z)- (9CI)
 MF C20 H32 O2

Double bond geometry as shown.



L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Oxygenase, arachidonate 18-mono- (9CI)
 MF Unspecified
 CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Kinase (phosphorylating), PKC (Xenopus laevis clone X3 arachidonic acid-binding) (9CI)
 SQL 901
 MF Unspecified
 CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***


L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14-Eicosatetraenamide-N-t, N-(2-hydroxyethyl-1,1-t2)-, (all-Z)-
 (9CI)
 MF C22 H34 N O2 T3

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN DEA (human potassium channel TRAAK (TWIK-related arachidonic
 acid-stimulated K channel) cDNA) (9CI)
 SQL 1182
 MF Unspecified
 CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s stearidonic acid
      2 STEARIDONIC
      5576167 ACID
      7845 ACIDS
      5581876 ACID
            (ACID OR ACIDS)
L6      2 STEARIDONIC ACID
            (STEARIDONIC (W) ACID)

=> d scan
```

L6 2 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12,15-Octadecatetraenoic acid, (6Z,9Z,12Z,15Z)- (9CI)
 MF C18 H28 O2
 CI COM

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 2 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 8,11,14,17-Eicosatetraenoic acid, (8Z,11Z,14Z,17Z)- (9CI)
 MF C20 H32 O2
 CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


ALL ANSWERS HAVE BEEN SCANNED

```
=> s eicosapentaenoic acid
      827 EICOSAPENTAENOIC
      5576167 ACID
      7845 ACIDS
      5581876 ACID
            (ACID OR ACIDS)
L7      811 EICOSAPENTAENOIC ACID
            (EICOSAPENTAENOIC (W) ACID)


=> d scan
```

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14,17-Eicosapentaenoic acid, (2E)-3-hydroxy-2-[(1E)-1-oxo-9-octadecenyl]oxy]propyl ester, (5Z,8Z,11Z,14Z,17Z)- (9CI)
 MF C41 H68 O5

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14,17-Eicosapentaenoic acid, (2E)-3-[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-[(11Z,14Z)-1-oxo-11,14-eicosadienyl]oxy]propyl ester, (5Z,8Z,11Z,14Z,17Z)- (9CI)
 MF C45 H76 N O8 P

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14,17-Eicosapentaenoic acid, octadecyl ester, (5E,8E,11E,14E,17E)- (9CI)
 MF C38 H66 O2

Double bond geometry as shown.




PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Eicosapentaenoic acid, 2-[(1-oxohexadecyl)oxy]-1,3-propanediyl ester (9CI)
 MF C59 H94 O6
 CI IDS

CH 1



L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14,17-Eicosapentaenoic acid, 16-hydroxy-, (all-Z)- (9CI)
 MF C20 H30 O3


Double bond geometry as shown.



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Eicosapentaenoic acid, hexacosyl ester (9CI)
 MF C46 H82 O2
 CI IDS

CH 1




L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 6,9,12,15,18-Eicosapentaenoic acid, labeled with deuterium, (all-Z)- (9CI)
 MF C20 H30 O2

Double bond geometry as shown.



L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,12,14,17-Eicosapentaenoic acid, 11-hydroperoxy-, (E,Z,Z,Z,Z)- (9CI)
 MF C20 H30 O4

Double bond geometry as shown.




***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14,17-Eicosapentaenoic acid, ester with 1,2,3-propanetriol
 monodocosanoate monohexadecanoate, (all-Z)- (9CI)
 MF C61 H106 O6
 CI IDS

CH 1


Double bond geometry as shown.



CH 2

HO₂C-(CH₂)₁₄-Me

CH 3




CH 4

CH 5

HO₂C-(CH₂)₂₀-Me

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,10,14,17-Eicosapentaenoic acid, 12,13-dihydroxy-,
 [S-(R*,S*-(Z,E,Z,Z,Z))]- (9CI)
 MF C20 H30 O4

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0


=> s docosapentaenoic acid n-3
275 DOCOSAPENTAENOIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
4275795 N
11229525 3
L8 0 DOCOSAPENTAENOIC ACID N-3
(DOCOSAPENTAENOIC (W) ACID (W) N (W) 3)

=> s docosapentaenoic acid
275 DOCOSAPENTAENOIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
L9 269 DOCOSAPENTAENOIC ACID
(DOCOSAPENTAENOIC (W) ACID)

=> d scan

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 7,10,12,15,19-Docosapentaenoic acid, 17-hydroperoxy-14-hydroxy- (9CI)
 MF C22 H34 O5

PAGE 1-A



PAGE 1-B


— (CH₂)₅-CO₂H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 7,11,13,16,19-Docosapentaenoic acid, 10-hydroxy-, methyl ester, (7Z,10R,11E,13Z,16Z,19Z)- (9CI)
 MF C23 H36 O3


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Docosapentaenoic acid, ester with 1,2,3-propanetriol 1-(2-aminoethyl hydrogen phosphate) mono-(Z)-hexadecenoate, (Z,Z,Z,Z,Z,Z)- (9CI)
 MF C43 H74 N O8 P
 CI IDS

CM 1



CM 2

CM 3

HO₂C-(CH₂)₂₀-Me


CM 4

CM 5

HO₂C-(CH₂)₁₄-Me


L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 7,10,13,16,19-Docosapentaenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyloxy]methyl]-2-(1-octadecenyl)oxy]ethyl ester, (R-(7Z,10E,13Z,16Z,19Z))- (9CI)
 MF C45 H80 N O7 P

Absolute stereochemistry.
 Double bond geometry as described by E or Z.



PAGE 1-A


PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 7,10,13,16,19-Docosapentaenoic acid, 14-hydroxy- (9CI)
 MF C22 H34 O3

PAGE 1-A




PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16-Docosapentaenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxooctadecyl)oxy]ethyl ester (9CI)
 MF C45 H80 N O8 P
 CI COM

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 7,10,13,16,19-Docosapentaenoic acid, 1-(hydroxymethyl)-2-[(1-oxooctadecyl)oxy]ethyl ester, (R-(all-Z))- (9CI)
 MF C43 H74 O5

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16-Docosapentaenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxo-7,10,13,16-docosatetraenyl)oxy]ethyl ester, (all-Z)- (9CI)
 MF C49 H80 N O8 P

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,19-Docosapentaenoic acid, 14-hydroperoxy- (9CI)
 MF C22 H34 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Docosapentaenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-(9-octadecenyloxy)ethyl ester, [R-(all-E)]- (9CI)
 MF C45 H80 N O7 P
 CI 105

CH 1

Absolute stereochemistry.
 Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0


=> s docosahexaenoic acid
693 DOCOSAHEXAENOIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
L10 688 DOCOSAHEXAENOIC ACID
(DOCOSAHEXAENOIC (W) ACID)

=> d scan

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, monoester with
 1,2,3-propanetriol mono-octanoate, (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI)
 MF C33 H52 O5
 CI IDS

CH 1


Double bond geometry as shown.



CH 2

HO2C-(CH2)6-Me

CH 3




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9


L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 5,8,11,14,17,20-Docosahexaenoic acid, 22-hydroperoxy-, methyl ester,
 (5Z,8Z,11Z,14Z,17Z,20E)- (9CI)
 MF C23 H34 O4

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-
 aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[[[(9Z)-1-oxo-9-
 hexadecanoyl]oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI)
 MF C43 H72 N O8 P

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, ester with 1,2,3-propanetriol
 dihexadecadienoate, (all-Z)- (9CI)
 MF C57 H94 O6
 CI IDS

CH 1

Double bond geometry as shown.



CH 2



CH 3


CH 4

HO2C-(CH2)14-Me

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, monoester with
 1,2,3-propanetriol monooctadecanoate, [8-(all-Z)]- (9CI)
 MF C43 H72 O5
 CI IDS

CH 1


Double bond geometry as shown.



CH 2

HO2C-(CH2)16-Me


CH 3




L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, 2-[(1-oxo-9,12-octadecadienyl)oxy]-3-[(1-oxo-9-octadecenyl)oxy]propyl ester, (all-Z)- (9CI)
 MF C61 H100 O6

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, 3-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-[(1-oxo-4,7,10,13,16-docosapentaenyl)oxy]propyl ester, (all-Z)- (9CI)
 MF C49 H76 N O8 P

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 1-C




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, (16)-1-(hydroxymethyl)-1,2-ethanediyl ester, (4Z,4'Z,7Z,7'Z,10Z,10'Z,13Z,13'Z,16Z,16'Z,19Z,19'Z)- (9CI)
 MF C47 H68 O5

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,16,19-Docosahexaenoic acid, monoester with
 1,2,3-propanetriol monohexadecanoate mono-(9Z)-9-hexadecenoate,
 (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI)
 MF C57 H96 O6
 CI 105


CH 1

Double bond geometry as shown.




CH 2


Double bond geometry as shown.



CH 3




CH 4



L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 4,7,10,13,15,19-Docosahexaenoic acid, 17-(benzoyloxy)-, methyl ester,
 [8-(4Z,7Z,10Z,13Z,15Z,19Z)]- (9CI)
 MF C30 H38 O4

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

OME

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s columbinic acid
 3 COLUMBINIC
 5576167 ACID
 7845 ACIDS
 5581876 ACID
 (ACID OR ACIDS)
L11 3 COLUMBINIC ACID
 (COLUMBINIC (W) ACID)

=> d scan

L11 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cholest-5-en-3-ol (3.beta.)-, 5,9,12-octadecatrienoate, (Z,Z,E)- (9CI)
MF C45 H74 O2

PAGE 1-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L11 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,9,12-Octadecatrienoic acid, (5E,9Z,12Z)- (9CI)
MF C18 H30 O2
CI COM


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 7,11,14-Eicosatrienoic acid, (7E,11Z,14Z)- (9CI)
MF C20 H34 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s conjugated linoleic acid

130 CONJUGATED

514 LINOLEIC

5576167 ACID

7845 ACIDS

5581876 ACID

(ACID OR ACIDS)


L12

7 CONJUGATED LINOLEIC ACID

(CONJUGATED (W) LINOLEIC (W) ACID)

=> d scan

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11-Octadecadienoic acid (6CI, 8CI, 9CI)
MF C18 H32 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Fatty acids, tall-oil, polymers with bisphenol A, conjugated linoleic acid, epichlorohydrin and maleic anhydride
MF Unspecified
CI PMS, MAN, CTS


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Fatty acids, C16-18 and C18-unsatd., polymers with benzoic acid, conjugated linoleic acid, diethylene glycol, isophthalic acid, oleic acid, trimellitic anhydride, trimethylethane and trimethylolpropane
MF Unspecified
CI MAN, CTS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11-Octadecadienoic acid, (9Z,11E)- (9CI)
MF C18 H32 O2
CI COM

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Octadecadienoic acid (9CI)
 MF C18 H32 O2
 CI IDS, COM
 CM 1

HO₂C-(CH₂)₁₆-Me

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 10,12-Octadecadienoic acid, (10E,12Z)- (9CI)
 MF C18 H32 O2
 CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Castor oil, polymer with conjugated linoleic acid, glycerol and
 phthalic anhydride
 MF Unspecified
 CI PMS, MAN, CTS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ALL ANSWERS HAVE BEEN SCANNED

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

124.24

124.45

FILE 'CAPLUS' ENTERED AT 07:52:57 ON 23 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2002 VOL 137 ISS 13

FILE LAST UPDATED: 22 Sep 2002 (20020922/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 07:48:37 ON 23 SEP 2002)

FILE 'REGISTRY' ENTERED AT 07:48:44 ON 23 SEP 2002

L1	1 S ADRENIC ACID
L2	9 S PARINARIC ACID
L3	14 S GAMMA LINOLENIC ACID
L4	4 S DIHOMO GAMMA LINOLENIC ACID
L5	73 S ARACHIDONIC ACID
L6	2 S STEARIDONIC ACID
L7	811 S EICOSAPENTAENOIC ACID
L8	0 S DOCOSAPENTAENOIC ACID N-3
L9	269 S DOCOSAPENTAENOIC ACID
L10	688 S DOCOSAHEXAENOIC ACID
L11	3 S COLUMBINIC ACID
L12	7 S CONJUGATED LINOLEIC ACID

FILE 'CAPLUS' ENTERED AT 07:52:57 ON 23 SEP 2002

=> s l1

L13 160 L1

=> s l1 and l2

160 L1
239 L2
L14 2 L1 AND L2

=> d ibib abs hitstr 1-2

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:26284 CAPLUS
 DOCUMENT NUMBER: 126:47036
 TITLE: Preparation of 1,3-propanediol derivatives for transport of bioactive compounds
 INVENTOR(S): Horrobin, David Frederick; Manku, Mehar; McMordie, Austin; Knowles, Philip; Redden, Peter; Pitt, Andrea; Bradley, Paul; Wakefield, Paul
 PATENT ASSIGNEE(S): Scotia Holdings Plc, UK; Horrobin, David Frederick; Manku, Mehar; McMordie, Austin; Knowles, Philip; Redden, Peter; Pitt, Andrea; Bradley, Paul; Wakefield, Paul
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634846	A1	19961107	WO 1996-GB1053	19960501
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9603360	A	19960820	ZA 1996-3360	19960426
ZA 9603397	A	19960807	ZA 1996-3397	19960429
ZA 9603433	A	19960807	ZA 1996-3433	19960430
CA 2218699	AA	19961107	CA 1996-2218699	19960501
CA 2218702	AA	19961107	CA 1996-2218702	19960501
AU 9655080	A1	19961121	AU 1996-55080	19960501
AU 707600	B2	19990715		
EP 823889	A1	19980218	EP 1996-912139	19960501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1187813	A	19980715	CN 1996-194780	19960501
CN 1189148	A	19980729	CN 1996-195062	19960501
BR 9606607	A	19981215	BR 1996-6607	19960501
JP 11504914	T2	19990511	JP 1996-533121	19960501
NO 9705036	A	19971217	NO 1997-5036	19971031
PRIORITY APPLN. INFO.: GB 1995-8823 A 19950501				
GB 1995-17107 A 19950821				
GB 1996-5440 A 19960315				
WO 1996-GB1053 W 19960501				

AB The prepn. of 1,3-propanediol derivs., R1OCH2CH2CH2OR2 (R1 is an acyl or fatty alc. group derived from a C12-30 preferably a C16-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hydrogen, or an acyl or fatty alc. group the same as or different, from R1 or any other nutrient, drug or other bioactive residue) for use in therapy are described. Title compds. are prepd. via acylation of 1,3-propanediol with a fatty acid followed by reaction with a bioactive compd. Title compds. are capable of crossing lipid membranes as in the skin and blood-brain


L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:740363 CAPLUS
 DOCUMENT NUMBER: 126:11535
 TITLE: Fatty acid salts of N-methylglucamine
 INVENTOR(S): Horrobin, David Frederick; Knowles, Philip; Manku, Mehar; Bonnett, Raymond; Stewart, John Charles Marshall
 PATENT ASSIGNEE(S): Scotia Holdings Plc, UK
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9633155	A1	19961024	WO 1996-GB952	19960419
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9603103	A	19960830	ZA 1996-3103	19960418
CA 2218636	AA	19961024	CA 1996-2218636	19960419
AU 9653425	A1	19961107	AU 1996-53425	19960419
AU 716680	B2	20000302		
BR 9606609	A	19971118	BR 1996-6609	19960419
EP 821663	A1	19980204	EP 1996-910125	19960419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11503747	T2	19990330	JP 1996-531568	19960419
US 5990164	A	19991123	US 1998-930701	19980317
PRIORITY APPLN. INFO.: GB 1995-8023 19950420				
WO 1996-GB952 19960419				

AB N-methylglucamine salts of polyunsatd. essential fatty acids having 16 to 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, and their derivs. were prepd. to provide water-sol. derivs. with improved formulation properties. Thus, N-methylglucamine was treated with docosahexaenoic acid to give the salt.
 IT 593-38-4, .alpha.-Parinaric acid 2091-25-0, Adrenic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of N-methylglucamine salts of unsatd. fatty acids)
 RN 593-38-4 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 2091-25-0 CAPLUS
 CN 9,10,13,16-Docosatetraenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)


L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS (Continued)

barrier.
 IT 2091-25-0, Adrenic acid 18427-44-6, Parinaric acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of 1,3-propanediol derivs. for transport of bioactive compds.)
 RN 2091-25-0 CAPLUS
 CN 7,10,13,16-Docosatetraenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 18427-44-6 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



=> d his

(FILE 'HOME' ENTERED AT 07:48:37 ON 23 SEP 2002)

FILE 'REGISTRY' ENTERED AT 07:48:44 ON 23 SEP 2002

L1 1 S ADRENIC ACID
L2 9 S PARINARIC ACID
L3 14 S GAMMA LINOLENIC ACID
L4 4 S DIHOMO GAMMA LINOLENIC ACID
L5 73 S ARACHIDONIC ACID
L6 2 S STEARIDONIC ACID
L7 811 S EICOSAPENTAENOIC ACID
L8 0 S DOCOSAPENTAENOIC ACID N-3
L9 269 S DOCOSAPENTAENOIC ACID
L10 688 S DOCOSAHEXAENOIC ACID
L11 3 S COLUMBINIC ACID
L12 7 S CONJUGATED LINOLEIC ACID

FILE 'CAPLUS' ENTERED AT 07:52:57 ON 23 SEP 2002

L13 160 S L1
L14 2 S L1 AND L2

=> s 12

L15 239 L2

=> s 13

L16 4896 L3

=> s 14

L17 2711 L4

=> s 15

L18 35302 L5

=> s 16

L19 1294 L6

=> s 17

L20 8982 L7

=> s 19

L21 3640 L9

=> s 110

L22 9802 L10

=> s 111

L23 46 L11

=> s 112

L24 759 L12

=> s 12 and 13

239 L2

4896 L3

L25 17 L2 AND L3


```
=> s 125 and 14
      2711 L4
L26      7 L25 AND L4

=> s 126 and 15
      35302 L5
L27      6 L26 AND L5

=> s 127 and 16
      1294 L6
L28      2 L27 AND L6

=> s 128 not 114
L29      1 L28 NOT L14

=> d ibib abs hitstr
```

L29 ANSWER 1 OF 1 CAPIUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:465570 CAPIUS
 DOCUMENT NUMBER: 121:65570
 TITLE: Pharmaceutical compositions containing fatty acids and heparin
 INVENTOR(S): Horrobin, David F.; Scott, Catherine A.
 PATENT ASSIGNEE(S): Scotia Holdings PLC, UK
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPYXOW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 585058	A1	19940302	EP 1993-306570	19930819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9344807	A1	19940303	AU 1993-44807	19930823
AU 666961	B2	19960229		
CA 2104747	AA	19940226	CA 1993-2104747	19930824
NO 9303017	A	19940228	NO 1993-3017	19930824
JP 06157305	A2	19940603	JP 1993-209487	19930824
ZA 9306232	A	19940321	ZA 1993-6232	19930825
CN 1090776	A	19940817	CN 1993-118329	19930825
PRIORITY APPLN. INFO.:				
			GB 1992-18065	19920825
			GB 1992-22655	19921028

AB A method of safe i.v. administration of fatty acids or salts and deriva. thereof or conjugated fatty acids, is comprised of i.v. or sub-cutaneous administration of heparin (I) in a dose of 1,000-20,000 IU, preferably 3000-10,000 IU or equiv. anticoagulant dose of I-like proteins or peptides prior to infusion of the fatty acids. This method is useful in the treatment of cancer, viral infections and other disorders, requiring maintenance of high plasma fatty acid levels. Ampules contg. a soln. of 5-500mg/mL Li .gamma.-linolenate in 0.9% saline soln. were prepd. which could be added to i.v. fluids to achieve final concn. of 5-20mg/mL to patients pretreated with I at a dose of 3000-10,000IU.


IT 506-26-3, .gamma.-Linolenic acid 506-32-1, Arachidonic acid 1783-84-2, Dihomo-.gamma.-linolenic acid 18427-44-6, Parinaric acid 20290-75-9, Stearidonic acid

RL: BIOL (Biological study)

(pharmaceutical compn. contg., heparin for safe administration of)

RN 506-26-3 CAPIUS
 CN 6,9,12-Octadecatetraenoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 506-32-1 CAPIUS
 CN 5,8,11,14-Eicosatetraenoic acid, (5Z,8Z,11Z,14Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L29 ANSWER 1 OF 1 CAPIUS COPYRIGHT 2002 ACS (Continued)



RN 1783-84-2 CAPIUS
 CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 18427-44-6 CAPIUS
 CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 20290-75-9 CAPIUS
 CN 6,9,12,15-Octadecatetraenoic acid, (6Z,9Z,12Z,15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d ibib abs hitstr 125 1-17

L25 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:466707 CAPLUS
 DOCUMENT NUMBER: 137:37683
 TITLE: Method of potentiating the action of 2-methoxyoestradiol, statins and c-peptide of proinsulin
 INVENTOR(S): Das, Undurti Narasimha
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002077317	A1	20020620	US 2000-737671	20001215

AB Disclosed is a method of stabilizing and potentiating the actions of 2-methoxyoestradiol, statins, H2 blockers, and C-peptide of proinsulin which have modifying influence on angiogenesis and inhibiting the growth of tumor cells, peptic ulcer disease, diabetes mellitus and its complications, and Alzheimer's disease as applicable by using in coupling conjugation certain polyunsatd. fatty acids (PUFAs) chosen from linoleic acid, .gamma.-linolenic acid, dihomo-.gamma.-linolenic acid, arachidonic acid, .alpha.-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid or conjugated linoleic acid in predetd. quantities. Uncontrolled angiogenic activity and tumor growth can be inhibited by the selective use of a mixt. of PUFAs with anti-angiogenic substances used selectively, and optionally in conjunction with predetd. anti-cancer drugs. A preferred method of administration of the mixt. to treat a tumor is intra-arterial administration into an artery which provides the main blood supply for the tumor. The method will also be useful in the treatment of peptic ulcer disease, diabetes mellitus and its complications and Alzheimer's disease.

IT 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric acid 1783-84-2, Dihomo-.gamma.-linolenic acid
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyunsatd. fatty acids for potentiating actions of anigogenesis inhibitors and antiulcer agents and antidiabetics and mental disease drugs)

RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatetraenoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 593-38-4 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L25 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

HO2C-(CH2)7-Z-E-E-Z-Et

RN 1783-84-2 CAPLUS
 CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:545113 CAPLUS
 DOCUMENT NUMBER: 135:224700
 TITLE: Lipid and fatty acid analysis of fresh and frozen-thawed immature oocytes and in vitro matured bovine oocytes
 AUTHOR(S): Kim, J. Y.; Kinoshita, M.; Ohnishi, M.; Fukui, Y.
 CORPORATE SOURCE: Laboratory of Animal Genetics and Reproduction, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Japan
 SOURCE: Reproduction (Cambridge, United Kingdom) (2001), 122(1), 131-138
 CODEN: RCUKBS; ISSN: 1470-1626
 PUBLISHER: Journals of Reproduction and Fertility Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The lipid content and fatty acid compn. of fresh immature and in vitro matured bovine oocytes cultured in media with or without serum, and also those of frozen-thawed immature oocytes were analyzed. All oocytes were ranked (A or B) on the basis of their cytoplasmic quality. Fatty acid compn. (mol %; wt./wt.) in the total lipid fraction was analyzed by gas chromatog. Triglyceride, total cholesterol, phospholipid (phosphocholine-contg. phospholipid) and non-esterified fatty acid contents of immature and in vitro matured oocytes were detd. using lipid anal. kits. Phosphocholine-contg. phospholipid and non-esterified fatty acid contents were detd. in frozen-thawed immature bovine oocytes. Palmitic acid was the most abundant fatty acid in immature oocytes (A: 35%, B: 36%), and in in vitro matured oocytes cultured in the medium contg. serum (A: 36%, B: 35%) or polyvinyl alc. (A: 33%, B: 36%). Oleic acid was the second most abundant fatty acid in all A ranked oocytes, whereas stearic acid was the second most abundant fatty acid in all B ranked oocytes. There were significant differences (P < 0.05) in linoleic and arachidonic acid fractions between A and B ranked immature oocytes. In vitro matured oocytes had significantly (P < 0.05) lower proportions of linoleic and arachidonic acids, and significantly (P < 0.01) lower contents of triglyceride and total cholesterol compared with those of immature oocytes. The fatty acid compn. of in vitro matured oocytes cultured in medium contg. fetal calf serum or polyvinyl alc. was similar, but significant differences (P < 0.01) in triglyceride and the total cholesterol content were obsd. There was a significant decrease (P < 0.05) in the arachidonic acid proportion in frozen-thawed immature oocytes compared with that in fresh immature oocytes. In addn., significant (P < 0.05) decreases in both phospholipid (15.8-10.6 pmol) and non-esterified fatty acid (11.0-4.1 pmol) were found in frozen-thawed immature oocytes. The results indicate that lipids are available for use as an energy source for maturation and that serum lipids are incorporated into the oocyte cytoplasm during in vitro maturation. The changes in the lipid content (mainly phospholipid) and fatty acid compn. were also obsd. in frozen-thawed immature oocytes. The study indicates that the alteration of fatty acid compn. in bovine oocytes might improve maturation and cryopreservation.

IT 506-26-3, .gamma.-Linolenic acid 1783-84-2
 18427-44-6, Parinaric acid
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
 (lipid and fatty acid anal. of fresh and frozen-thawed immature and in vitro matured bovine oocytes)

RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatetraenoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

L25 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

Double bond geometry as shown.


Me-(CH2)4-Z-Z-Z-(CH2)4-CO2H

RN 1783-84-2 CAPLUS
 CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

HO2C-(CH2)6-Z-Z-Z-(CH2)4-Me

RN 18427-44-6 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:507528 CAPLUS

DOCUMENT NUMBER: 135:97483

TITLE: Composition for stabilizing and potentiating the action of anti-angiogenic substances by polyunsaturated fatty acids

INVENTOR(S): Das, Undurti N.

PATENT ASSIGNEE(S): EFA Sciences LLC, USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXK02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049284	A1	20010712	WO 2000-US1037	20000118
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GA, GM, GW, ML, MR, NE, SN, TD, TG				
US 6380253	B1	20020430	US 2000-478291	20000105

PRIORITY APPLM. INFO.:

AB Disclosed is a method of stabilizing and potentiating action of mols. of known anti-angiogenic substances such as Angiostatin or Endostatin by using in coupling conjugation with cis-unsatd. fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, .gamma.-linolenic acid, dihomo-.gamma.-linolenic acid, arachidonic acid, .alpha.-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetd. quantities. Preferably, the c-UFAs are in the form of polyunsatd. fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetd. anti-cancer drugs. For treatment of glioma, a sodium salt of a PUFA is preferred to form an admixt. with an anti-angiogenic substance and a selected anti-cancer drug. For a non-glioma type of cell proliferation disorder, a sodium, potassium or lithium salt of a PUFA is preferred to form an admixt. with an anti-angiogenic substance. Anti-angiogenic substances envisaged in this invention include Angiostatin, Endostatin, platelet factor-4, TNP-470, thalidomide, interleukin-12 and metalloproteinase inhibitors. A preferred method of administration of the mixt. to treat a tumor is intra-arterial administration into an artery which provides the main blood supply for the tumor.

IT 506-26-3, .gamma.-Linolenic acid 593-38-4, Cis-Parinaric acid 1783-84-2, Dihomo-.gamma.-linolenic acid

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyunsatd. fatty acids for potentiating action of anti-angiogenic substances)

L25 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:462668 CAPLUS

DOCUMENT NUMBER: 135:207092

TITLE: Uterocalin, a lipocalin provisioning the preattachment equine conceptus: fatty acid and retinol binding properties, and structural characterization

AUTHOR(S): Suire, Sabine; Stewart, Francesca; Beauchamp, Jeremy; Kennedy, Malcolm W.

CORPORATE SOURCE: Babraham Institute, Cambridge, CB2 4AT, UK

SOURCE: Biochemical Journal (2001), 355(2), 369-376

CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The equine conceptus is surrounded by a fibrous capsule that persists until about day 20 of pregnancy, whereupon the capsule is lost, the conceptus attaches to the endometrium and placental development proceeds. Before attachment, the endometrium secretes in abundance a protein of the lipocalin family, uterocalin. The cessation of secretion coincides with the end of the period during which the conceptus is enclosed in its capsule, suggesting that uterocalin is essential for the support of the embryo before direct contact between maternal and fetal tissues is established. Using recombinant protein and fluorescence-based assays, we show that equine uterocalin binds the fluorescent fatty acids 11-(dansylamino)undecanoic acid, dansyl-D,L-.alpha.-amino-octanoic acid and cis-parinaric acid, and, by competition, oleic, palmitic, arachidonic, docosahexaenoic, .gamma.-linolenic, cis-eicosapentaenoic and linoleic acids. Uterocalin also binds all-trans-retinol, the binding site for which is coincident or interactive with that for fatty acids. Mol. modeling and intrinsic fluorescence anal. of the wild-type protein and a Trp .fwdarw. Glu mutant protein indicated that uterocalin has an unusually solvent-exposed Trp side chain projecting from its large helix directly into solvent. This feature is unusual among lipocalins and might relate to binding to, and uptake by, the trophoblast. Uterocalin therefore has the localization and binding activities for the provisioning of the equine conceptus with lipids including those essential for morphogenesis and pattern formation. The possession of a fibrous capsule surrounding the conceptus might be an ancestral condition in mammals; homologs of uterocalin might be essential for early development in marsupials and in eutherians in which there is a prolonged preimplantation period.

IT 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric acid


RI: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(fatty acid and retinol binding properties, and structural characterization of uterocalin, a lipocalin provisioning the preattachment equine conceptus)

RN 506-26-3 CAPLUS

CN 6,9,12-Octadecatrienoic acid, (62,92,122)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 593-38-4 CAPLUS


CN 9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,15Z)- (9CI) (CA INDEX NAME)

L25 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 506-26-3 CAPLUS

CN 6,9,12-Octadecatrienoic acid, (62,92,122)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 593-38-4 CAPLUS

CN 9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,15Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 1783-84-2 CAPLUS

CN 8,11,14-Eicosatrienoic acid, (82,11Z,14Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

Double bond geometry as shown.




REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L25 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:247799 CAPLUS
 DOCUMENT NUMBER: 132:255962
 TITLE: Soft capsule of Lithospermum euchromum seed oil
 INVENTOR(S): Tong, Enguo
 PATENT ASSIGNEE(S): Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 5 pp.
 CODEN: CNOKEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1180536	A	19980506	CN 1996-119487	19961017
AB				
Soft capsule of Lithospermum euchromum seed oil comprises cetyllic acid 4.8-5.2, stearic acid 2.1-2.6, oleic acid 11.4-12.7, vitamin E 1, linoleic acid 20-20.7, .alpha.-linolenic acid 13.7-14.1, .gamma.-linolenic acid 30-31.9, parinaric acid 12.7-13.7, eicosenoic acid 1.0-1.3, and water to 100%.				
IT				
506-26-3, .gamma.-Linolenic acid 18427-44-6, Parinaric acid				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(soft capsule of Lithospermum euchromum seed oil)				
RN				
506-26-3 CAPLUS				
CN				
6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



RN 18427-44-6 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

Me-(CH2)4-Z-Z-Z-(CH2)4-CO2H

RN 593-38-4 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

HO2C-(CH2)7-Z-E-E-Z-Et

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:98300 CAPLUS
 DOCUMENT NUMBER: 132:132356
 TITLE: Chemically induced intracellular hyperthermia for therapeutic and diagnostic use
 INVENTOR(S): Bachynsky, Nicholas; Roy, Woodie
 PATENT ASSIGNEE(S): Texas Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006143	A1	20000210	WO 1999-US16940	19990727
V:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9951318	A1	20000221	AU 1999-51318	19990727
AU 750313	B2	20000718		
EP 1098641	A1	20010516	EP 1999-935949	19990727
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1998-94286P P 19980727
 WO 1999-US16940 W 19990727

AB Therapeutic pharmacol. agents and methods are disclosed for chem. induction of intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy, and other medical conditions. A process and compn. are provided for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chem. generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, esp. 2,4-dinitrophenol, and their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chem. induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:576773 CAPLUS
 DOCUMENT NUMBER: 131:194282
 TITLE: Cancer management with tamoxifen or other antiestrogen and .gamma.-linolenic acid or other unsaturated fatty acid
 INVENTOR(S): Horrobin, David Frederick; Bryce, Richard; Hartley, John
 PATENT ASSIGNEE(S): Scotia Holdings PLC, UK
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944600	A1	19990910	WO 1999-GB563	19990224
V:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2322856	AA	19990910	CA 1999-2322856	19990224
AU 9926320	A1	19990920	AU 1999-26320	19990224
EP 1058545	A1	20001213	EP 1999-906355	19990224
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002505279	T2	20020219	JP 2000-534202	19990224
ZA 9901619	A	20000120	ZA 1999-1619	19990301
PRIORITY APPLN. INFO.:			GB 1998-4361	A 19980302
			WO 1999-GB563	W 19990224


AB The invention provides tamoxifen and .gamma.-linolenic acid, giving strong synergistic action in cancer management, and prepn. of medicaments therefor. Other disclosed antiestrogens include e.g. toremifene and 4-hydroxytamoxifen; other unsatd. fatty acid include e.g. dihomogamma.-linolenic acid and eicosapentaenoic acid.

IT 506-26-3, .gamma.-Linolenic acid 18427-44-6, Parinaric acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tamoxifen or other antiestrogen and .gamma.-linolenic acid or other unsatd. fatty acid for cancer management)

RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 1783-84-2 CAPLUS
 CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)


L25 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

Double bond geometry as shown.



RN 18427-44-6 CAPLUS


CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:399835 CAPLUS

DOCUMENT NUMBER: 131:157149

TITLE: A comparative study of fatty acids in human breast

milk and breast milk substitutes in Kuwait

AUTHOR(S): Hayat, Lamya; Al-Sughayer, Mona; Afzal, Mohammed

CORPORATE SOURCE: Biochemistry Department, Faculty of Science, Kuwait

University, Al-Safat, 13060, Kuwait

SOURCE: Nutrition Research (New York) (1999), 19(6), 827-841

CODEN: NTRSDC; ISSN: 0271-5317

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Specific stds. of infant formula lack detailed recommendations about fatty acids in formula preps. except for linoleic acid [18:2(n-6)]. Many fatty acids were known to be very important in early development. Human breast milk is considered the best model for designing breast milk substitutes with ideal nutritive value. Fatty acid compn. of human milk obtained from 19 full breast feeding Kuwaiti mothers and in 22 adapted formulas (breast milk substitutes) was detd. by using capillary gas chromatog. Palmitic acid (16:0), and as a consequence, total satd. fatty acids were found to be lower in human milk than formula milk. However, total mono- and polyunsatd. fatty acids were found to be higher in human milk than in formula milk. Linoleic acid [18:2(n-6)] content in formula milk was similar to human milk, while .alpha.-linolenic acid [18:3, (n-3)] showed a higher percentage in formula milk. Evidently formula milk preps. provide essential fatty acids for infants in adequate amts. as a results of their fat blend. Formula milk tends to contain lower percentages of cis- and trans-isomeric fatty acids compared to human milk. In contrast to human milk, most formulas lacked physiol. important long-chain polyunsatd. fatty acids (LCP).


IT 506-26-3 1783-84-2 18427-44-6, Parinaric acid
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(comparative study of fatty acids in human breast milk and breast milk substitutes in Kuwait)

RN 506-26-3 CAPLUS

CN 6,9,12-Octadecatetraenoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 1783-84-2 CAPLUS

CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 18427-44-6 CAPLUS

L25 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:511859 CAPLUS

DOCUMENT NUMBER: 129:241957

TITLE: cis-Parinaric acid is a ligand for the human peroxisome proliferator activated receptor .gamma.: development of a novel spectrophotometric assay for the discovery of PPAR.gamma. ligands

AUTHOR(S): Palmer, Colin N. A.; Wolf, C. Roland

CORPORATE SOURCE: Ninewells Hospital and Medical School, Biomedical

Research Centre and ICRF Molecular Pharmacology Unit,

University of Dundee, Dundee, DD1 9SY, UK

SOURCE: FEBS Letters (1998), 431(3), 476-480

CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Peroxisome proliferator activated receptor .gamma. (PPAR.gamma.) is the subject of intense investigation as a target for drugs against diabetes, atherosclerosis and cancer. For this reason there is considerable interest in the spectrum of compds. that bind this receptor. In this paper we have identified cis-parinaric acid (CPA) as a novel hPPAR.gamma. ligand. The binding of this fatty acid to the receptor increases its fluorescence and causes a shift in the UV spectrum. This spectral shift is reversible by competition with other known ligands for PPAR.gamma.. This report represents the first direct demonstration of a fatty acid binding to PPAR.gamma..


IT 593-38-4, cis-Parinaric acid
RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)

(cis-parinaric acid is a ligand for human peroxisome proliferator activated receptor .gamma. from development of a novel spectrophotometric assay for discovery of PPAR.gamma. ligands)

RN 593-38-4 CAPLUS

CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 506-26-3, .gamma.-Linolenic acid

RL: ARG (Analytical reagent use); BPR (Biological process); BSU

(Biological study, unclassified); ANST (Analytical study); BIOL


(Biological study); PROC (Process); USES (Uses)

(cis-parinaric acid is a ligand for human peroxisome proliferator activated receptor .gamma. from development of a novel spectrophotometric assay for discovery of PPAR.gamma. ligands)

RN 506-26-3 CAPLUS

CN 6,9,12-Octadecatetraenoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

L25 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 1998:366938 CAPLUS
 DOCUMENT NUMBER: 129:156531
 TITLE: Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism
 AUTHOR(S): Hawkins, R. A.; Sangster, Kathryn; Arends, M. J.
 CORPORATE SOURCE: University Department of Surgery, Royal Infirmary of Edinburgh NHS Trust, Edinburgh, EH3 9YW, UK
 SOURCE: Journal of Pathology (1998), 185(1), 61-70
 CODEN: JPTLAS; ISSN: 0022-3417
 PUBLISHER: John Wiley & Sons Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Polyunsatd. fatty acids (PUFAs), reported to be cytotoxic at micromolar concns. for cancer cells in vitro and in vivo, are currently being tested in clin. trials as anti-cancer agents. This study has shown that seven PUFAs all inhibited the growth in vitro of three pancreatic cancer cell lines and the HL-60 leukemic cell line. Five PUFAs induced cell death within 20-30 h, but two less potent PUFAs induced death between 50 and 75 h. Apoptosis was demonstrated to be the mode of cell death by light, UV fluorescence, and electron microscopy, together with studies of DNA fragmentation. In a time-course study of PUFA-treated Mia-Pa-Ca-2 cells, apoptosis accounted for an av. of 80 per cent of the loss of viability, with "secondary necrosis", a feature of late apoptosis, apparently accounting for the remainder. Correlations were found between the no. of fatty acid double bonds and the proportion of cells undergoing apoptosis induced in both Mia-Pa-Ca-2 cells (R=0.88) and HL-60 cells (R=0.85) and inversely with the micromolar concns. of PUFAs required for 50 per cent inhibition of growth (IC50) of Mia-Pa-Ca-2 cells (R=-0.73). Cell death was preceded by progressively increasing lipid peroxidn. The extent of PUFA-induced lipid peroxidn., measured as malondialdehyde (MDA), also correlated with the proportion of apoptosis induced in Mia-Pa-Ca-2 cells (R=0.69) or HL-60 cells (R=0.64), as well as with the no. of fatty acid double bonds (R=0.82). PUFA-induced apoptosis was oxidative, being blocked by both vitamin E acetate and sodium selenite, the latter in a critically time-dependent manner. The cytotoxic effects of exposure to a PUFA and to .gamma.-irradn. simultaneously with, or prior to, the addn. of PUFA produced a significantly greater cell kill than either agent alone.

IT 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (apoptotic death of pancreatic cancer cells induced by polyunsatd. fatty acids varies with double bond no. and involves oxidative mechanism in relation to enhancement by .gamma.-irradn.)

RW 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L25 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 593-38-4 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:26284 CAPLUS
 DOCUMENT NUMBER: 126:47036
 TITLE: Preparation of 1,3-propanediol derivatives for transport of bioactive compounds
 INVENTOR(S): Horrobin, David Frederick; Manku, Meharg; McMordie, Austin; Knowles, Philip; Redden, Peter; Pitt, Andrea; Bradley, Paul; Wakefield, Paul
 PATENT ASSIGNEE(S): Scottis Holdings Plc, UK; Horrobin, David Frederick; Manku, Meharg; McMordie, Austin; Knowles, Philip; Redden, Peter; Pitt, Andrea; Bradley, Paul; Wakefield, Paul
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634846	A1	19961107	WO 1996-GB1053	19960501
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9603360	A	19960820	ZA 1996-3360	19960426
ZA 9603397	A	19960807	ZA 1996-3397	19960429
ZA 9603433	A	19960807	ZA 1996-3433	19960430
CA 2218699	AA	19961107	CA 1996-2218699	19960501
CA 2218702	AA	19961107	CA 1996-2218702	19960501
AU 9655080	A1	19961121	AU 1996-55080	19960501
AU 707600	B2	19990715		
EP 823889	A1	19980218	EP 1996-912139	19960501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1187813	A	19980715	CN 1996-194780	19960501
CN 1189148	A	19980729	CN 1996-195062	19960501
BR 9606607	A	19981215	BR 1996-6607	19960501
JP 11504914	T2	19990511	JP 1996-533121	19960501
NO 9705036	A	19971217	NO 1997-5036	19971031
PRIORITY APPLN. INFO.:				
			GB 1995-8823	A 19950501
			GB 1995-17107	A 19950821
			GB 1996-5440	A 19960315
			WO 1996-GB1053	W 19960501

AB The prepn. of 1,3-propanediol derivs., R1OCH2CH2CH2OR2 (R1 is an acyl or fatty alc. group derived from a C12-30 preferably a C16-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hydrogen, or an acyl or fatty alc. group the same as or different, from R1 or any other nutrient, drug or other bioactive residue) for use in therapy are described. Title compds. are prepd. via acylation of 1,3-propanediol with a fatty acid followed by reaction with a bioactive compd. Title compds. are capable of crossing lipid membranes as in the skin and blood-brain barrier.

IT 506-26-3, .gamma.-Linolenic acid 18427-44-6, Parinaric acid
 RL: RCT (Reactant); RACT (Reactant or reagent)

L25 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
(prepn. of 1,3-propanediol derivs. for transport of bioactive compds.)
RN 506-26-3 CAPLUS
CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 18427-44-6 CAPLUS
CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C-(CH2)7-CH=CH-CH=CH-CH=CH-CH=CH-Et

L25 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:740363 CAPLUS
DOCUMENT NUMBER: 126:11535
TITLE: Fatty acid salts of N-methylglucamine
Horrobin, David Frederick; Knowles, Philip; Manku, Mehser, Bonnett, Raymond; Stewart, John Charles Marshall
INVENTOR(S):
PATENT ASSIGNEE(S): Scotia Holdings PLC, UK
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9633155	A1	19961024	WO 1996-GB952	19960419
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9603103	A	19960830	ZA 1996-3103	19960418
CA 2218636	AA	19961024	CA 1996-2218636	19960419
AU 9653425	A1	19961107	AU 1996-53425	19960419
AU 716680	B2	20000302		
BR 9606609	A	19971118	BR 1996-6609	19960419
EP 821663	A1	19980204	EP 1996-910125	19960419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11503747	T2	19990330	JP 1996-531568	19960419
US 5990164	A	19991123	US 1998-930701	19980317
PRIORITY APPL. INFO.:			GB 1995-8023	19950420
			WO 1996-GB952	19960419

AB N-methylglucamine salts of polyunsatd. essential fatty acids having 16 to 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, and their derivs. were prepd. to provide water-sol. derivs. with improved formulation properties. Thus, N-methylglucamine was treated with docosahexaenoic acid to give the salt.

IT 506-26-3, .gamma.-Linolenic acid 593-38-4, .alpha.-Parinaric acid 1783-84-2, Dihomo-.gamma.-linolenic acid RL: RCT (Reactant), RACT (Reactant or reagent)
(prepn. of N-methylglucamine salts of unsatd. fatty acids)

RN 506-26-3 CAPLUS
CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 593-38-4 CAPLUS
CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)


L25 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
NAME)

Double bond geometry as shown.



RN 1783-84-2 CAPLUS
CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L25 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:69426 CAPLUS
DOCUMENT NUMBER: 122:127257
TITLE: The activation of porcine pancreatic lipase by cis-unsaturated fatty acids
AUTHOR(S): van Kuiken, Barbara A.; Behnke, W. David
CORPORATE SOURCE: Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, 3110 Medical Sciences Bldg., 231 Bethesda Ave. (ML 524), Cincinnati, OH, 45267, USA
SOURCE: Biochimica et Biophysica Acta (1994), 1214(2), 148-60
CODEN: BBACAQ; ISSN: 0006-3002

DOCUMENT TYPE: Journal
LANGUAGE: English
AB In the presence of taurodeoxycholate, cis-unsatd. fatty acids increase porcine pancreatic lipase activity 15-fold at pH 7.5. This effect is saturable with a low proportion of fatty acid to substrate. The overall angle of the fatty acid, the position of its double bond and the presence of a carbonyl group were crit. factors in whether the fatty acid effectively increased lipase activity. When the substrate is emulsified by taurodeoxycholate, the pH optimum for lipase ranges from 6.2 to 7.0. In the presence of cis-unsatd. fatty acids, the overall activity of lipase increases, the pH optimum shifts, and the pH-activity curve becomes biphasic, with one optimum around pH 7.7, and the other around pH 8.8. Fluorescence studies indicate that fatty acids bind near arom. residues in lipase, particularly tryptophan. Using the fluorescent fatty acid cis-parinaric acid, it was detd. that multiple binding sites are present with Kd values of approx. 10⁻⁶ M. Far-UV CD studies indicate that in addn. to a high affinity fatty acid binding site with a Kd of approx. 10⁻⁶ M, there is also a low affinity binding site with a Kd of approx. 10⁻⁴ M. The far-UV CD data also show that cis-unsatd. fatty acids change the conformation of lipase. It is calcd. that the percentage of .alpha. helix decreases, and the amt. of .beta. sheet and .beta. turn structure increases. Because the three-dimensional crystal structure of lipase is known, a model is proposed to describe how cis-unsatd. fatty acids increase lipase activity.

IT 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric acid 18841-21-9, trans-Parinaric acid RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(activation of porcine pancreatic lipase by cis-unsatd. fatty acids)

RN 506-26-3 CAPLUS
CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 593-38-4 CAPLUS
CN 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L25 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 18841-21-9 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, (9E,11E,13E,15E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 1994:600766 CAPLUS
 DOCUMENT NUMBER: 121:200766
 TITLE: Oxidation of octadecatrienoic acids in the red alga Lithothamnion corallioides: structural and stereochemical studies of conjugated tetraene fatty acids and bis allylic hydroxy acids

AUTHOR(S): Hamberg, Mats
 CORPORATE SOURCE: Dep. Physiol. Chem., Karolinska Inst., Stockholm, S-171 77, Swed.
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1993), (24), 3065-72
 CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Enzymic oxidn. of (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid (.gamma.-linolenic acid) (I) in a prepn. of the red alga Lithothamnion corallioides Crouan led to the formation of (6Z,8E,10E,12Z)-octadeca-6,8,10,12-tetraenoic acid (II) and (11R,6Z,9Z,12Z)-hydroxyoctadeca-6,9,12-trienoic acid (III) as the main products. (9Z,12Z,15Z)-Octadeca-(9,12,15)-trienoic acid (.alpha.-linolenic acid) was oxidized in an analogous way to yield (9Z,11E,13E,15Z)-octadeca-9,11,13,15-tetraenoic acid (.alpha.-parinaric acid), (11S,9Z,12Z,15Z)-hydroxyoctadeca-9,12,15-trienoic acid, and (14R,9Z,12Z,15Z)-hydroxyoctadeca-9,12,15-trienoic acid. Isotope studies demonstrated that enzymic conversion of the acid I into the tetraene II was accompanied by stereospecific eliminations of the pro-S and pro-R hydrogens from C-8 and C-11, resp. The bis-allylic hydroxy acid III was formed from acid I by a reaction involving stereospecific elimination of the pro-S hydrogen from C-11 and incorporation of 1 atom of oxygen from water in the C-11 hydroxy group. Although the bis-allylic hydroxy esters were chem. convertible into conjugated tetraenes by rapid acid-catalyzed dehydration, enzymic formation of conjugated tetraenes and hydroxy acids in Lithothamnion occurred by independent pathways.

IT 506-26-3, .gamma.-linolenic acid
 RL: BIOL (Biological study)
 (enzymic oxidn.)
 RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT 26474-40-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and dihydroxylation)
 RN 26474-40-8 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, methyl ester, (2Z,2,E,E)- (8CI, 9CI) (CA INDEX NAME)

Double bond geometry as shown.


L25 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)




IT 2348-97-2P 7378-85-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 2348-97-2 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, methyl ester, (all-E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 7378-85-0 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, methyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:587306 CAPLUS
 DOCUMENT NUMBER: 121:187306
 TITLE: Cholesteryl esters of unsaturated fatty acids for use in pharmaceutical and nutritional composition
 INVENTOR(S): Horrobin, David Frederick
 PATENT ASSIGNEE(S): Scotia Holdings PLC, UK
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 606012	A1	19940713	EP 1993-310599	19931229
EP 606012	B1	19980715		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 168267	E	19980815	AT 1993-310599	19931229
ES 2119871	T3	19981016	ES 1993-310599	19931229
AU 9352763	A1	19940714	AU 1993-52763	19931230
AU 673555	B2	19961114		
ZA 9400025	A	19940819	ZA 1994-25	19940104
CA 2112824	AA	19940707	CA 1994-2112824	19940105
NO 9400035	A	19940707	NO 1994-35	19940105
RU 2142468	C1	19991210	RU 1994-61	19940105
JP 06234644	A2	19940823	JP 1994-338	19940106
CN 1096197	A	19941214	CN 1994-100242	19940106
US 5604216	A	19970218	US 1994-178553	19940106

PRIORITY APPLN. INFO.: GB 1993-125 A 19930106
 AB Cholesterol fatty acid esters, where the fatty acid is chosen from an essential fatty acid, parinaric acid, and columbinic acid may be used in therapy, esp. in the treatment of cancer and cardiovascular disease. For example, cholesteryl (z,z,z)-octadeca-6,9,12-trienoate was prepd. Formulations contg. cholesterol .gamma.-linolenic acid ester are also described.


IT 157904-24-0
 RL: BIOL (Biological study)
 (pharmaceutical and nutritional compns. contg.)
 RN 157904-24-0 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, 9,11,13,15-octadecatetraenoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




L25 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



IT 506-26-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with cholesterol)
 RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 1994:465570 CAPLUS
 DOCUMENT NUMBER: 121:65570
 TITLE: Pharmaceutical compositions containing fatty acids and heparin
 INVENTOR(S): Horrobin, David F.; Scott, Catherine A.
 PATENT ASSIGNEE(S): Scotia Holdings PLC, UK
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 585058	A1	19940302	EP 1993-306570	19930819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9344807	A1	19940303	AU 1993-44807	19930823
AU 666961	B2	19960229		
CA 2104747	AA	19940226	CA 1993-2104747	19930824
NO 9303017	A	19940228	NO 1993-3017	19930824
JP 06157305	A2	19940603	JP 1993-209487	19930824
ZA 9306232	A	19940321	ZA 1993-6232	19930825
CN 1090776	A	19940817	CN 1993-118329	19930825
			GB 1992-18065	19920825
			GB 1992-22655	19921028

AB A method of safe i.v. administration of fatty acids or salts and derivs. thereof or conjugated fatty acids, is comprised of i.v. or sub-cutaneous administration of heparin (I) in a dose of 1,000-20,000 IU, preferably 3000-10,000 IU or equiv. anticoagulant dose of I-like proteins or peptides prior to infusion of the fatty acids. This method is useful in the treatment of cancer, viral infections and other disorders, requiring maintenance of high plasma fatty acid levels. Ampules contg. a soln. of 5-500mg/mL Li .gamma.-linolenate in 0.9% saline soln. were prepd. which could be added to i.v. fluids to achieve final concn. of 5-20mg/mL to patients pretreated with I at a dose of 3000-10,000IU.

IT 506-26-3, .gamma.-linolenic acid 1783-84-2,
 Dihomo-.gamma.-linolenic acid 18427-44-6, Parinaric acid
 RL: BIOL (Biological study)
 (pharmaceutical compn. contg., heparin for safe administration of)
 RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 1783-84-2 CAPLUS
 CN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 18427-44-6 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 1990:411675 CAPLUS
 DOCUMENT NUMBER: 113:11675
 TITLE: Seasonal changes of the biochemical composition of marine particulate matter with special reference to fatty acids and sterols
 AUTHOR(S): Mayzaud, P.; Chanut, J. P.; Ackman, R. G.
 CORPORATE SOURCE: INRS, Rimouski, PQ, G5L 3A1, Can.
 SOURCE: Mar. Ecol.: Prog. Ser. (1989), 56(1-2), 189-204
 CODEN: MESEDT; ISSN: 0171-8630
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Seasonal changes in particulate size spectra, biochem. compn., and fatty acid and sterol content were followed from winter to fall in a small north Atlantic coastal basin. Strong seasonality, related to both spring bloom and summer biol. prodn., was recorded for most chem. and biochem. descriptors. Size spectra were generally characterized by dominance of small particles of equiv. diam. 6.35-25.4 .mu.m, except in early summer when an addnl. component of 32.0-64.0 .mu.m became important. Changes in either C:N ratio or carbohydrate:protein ratio indicated physiol. changes that could be related to nutrient limitation or senescence. The fatty acid and sterol compn. of the lipid fraction displayed major seasonal changes which reflected: (1) the seasonal heterogeneity of the taxonomic compn. of the particles; (2) the physiol. changes within each group of organisms; and (3) the various periods of low prodn. or bloom decay. Spring bloom prodn. of small to medium sized particles (12.7-50.8 .mu.m) was assocd. with C16 polyunsatd. acid, 20:5.omega.3, 24-methylenecholesterol, and desmosterol. Summer prodn. of small particles (2.0-6.4 .mu.m) was assocd. with C18 polyunsatd. acids, 22:6.omega.3, nor-24-cholesterol, and isofucoesterol, while the late winter-early spring period displayed close relationships between some sats. as well as monoenes (18:0, 18:1.omega.9, 20:1.omega.9, 22:1.omega.9) and cholesterol. Post-bloom decay assocd. another group of sats. and monoenes (14:0, 20:0, 22:0, 16:1.omega.9, 16:1t.DELTA.3) and .beta.-sitosterol. Overall particulate biochem. dynamics is discussed in terms of both phytoplankton metab. and trophic influence for the zooplankton consumers.

IT 506-26-3 18841-21-9
 RL: OCCU (Occurrence)
 (in lipids, from marine particulate matter, temporal variations of, phytoplankton metab. and compn. in relation to, in Bedford Basin, Nova Scotia, Canada)


RN 506-26-3 CAPLUS
 CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 18841-21-9 CAPLUS
 CN 9,11,13,15-Octadecatetraenoic acid, (9E,11E,13E,15E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
92.93	217.38

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-12.39	-12.39

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 08:00:54 ON 23 SEP 2002

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:04:26 ON 23 SEP 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:04:33 ON 23 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2

DICTIONARY FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 08945667c.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:04:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 222 TO ITERATE

100.0% PROCESSED 222 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

Examiner Anderson 703-605-1157

BATCH **COMPLETE**
PROJECTED ITERATIONS: 3547 TO 5333
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:04:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4226 TO ITERATE

100.0% PROCESSED 4226 ITERATIONS 52 ANSWERS
SEARCH TIME: 00.00.04

L3 52 SEA SSS FUL L1

=>
Uploading 08945667b.str

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 10:06:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 270 TO ITERATE

100.0% PROCESSED 270 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4415 TO 6385
PROJECTED ANSWERS: 33 TO 447

L5 12 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 10:06:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5273 TO ITERATE

100.0% PROCESSED 5273 ITERATIONS 170 ANSWERS
SEARCH TIME: 00.00.02

L6 170 SEA SSS FUL L4

=>
Uploading 08945667.str

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS
L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full
FULL SEARCH INITIATED 10:07:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4726 TO ITERATE

100.0% PROCESSED 4726 ITERATIONS 162 ANSWERS
SEARCH TIME: 00.00.01

L8 162 SEA SSS FUL L7

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	421.22	421.43

FILE 'CAPLUS' ENTERED AT 10:07:14 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2002 VOL 137 ISS 13
FILE LAST UPDATED: 22 Sep 2002 (20020922/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13
L9 33 L3

=> s 16
L10 147 L6

=> s 18
L11 315 L8

=> s 19 and diester
12340 DIESTER
10668 DIESTERS
19831 DIESTER
(DIESTER OR DIESTERS)
L12 0 L9 AND DIESTER

=> s 19 and di ester
389809 DI
3697 DIS
393362 DI
(DI OR DIS)
443266 ESTER
349309 ESTERS
643087 ESTER
(ESTER OR ESTERS)
735 DI ESTER
(DI(W)ESTER)
L13 0 L9 AND DI ESTER

=> s 110 and diester
12340 DIESTER
10668 DIESTERS
19831 DIESTER
(DIESTER OR DIESTERS)
L14 3 L10 AND DIESTER

=> s 19 and di-ester
389809 DI
3697 DIS
393362 DI
(DI OR DIS)
443266 ESTER
349309 ESTERS
643087 ESTER
(ESTER OR ESTERS)
735 DI-ESTER
(DI(W)ESTER)
L15 0 L9 AND DI-ESTER

=> s 111 and diester
12340 DIESTER
10668 DIESTERS
19831 DIESTER
(DIESTER OR DIESTERS)
L16 2 L11 AND DIESTER

=> s 111 and di-ester
389809 DI
3697 DIS
393362 DI
(DI OR DIS)
443266 ESTER
349309 ESTERS
643087 ESTER
(ESTER OR ESTERS)
735 DI-ESTER
(DI(W)ESTER)

L17 0 L11 AND DI-ESTER

=> d ibib abs hitstr 116 1-2

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:581721 CAPLUS
 DOCUMENT NUMBER: 123:106304
 TITLE: Esterification of oxysterols by human plasma
 lecithin-cholesterol acyltransferase
 AUTHOR(S): Sedláček, Stefan E.; Wasowicz, Erwin; Hulea, Stefan
 A.; Nishida, Hiro I.; Kummerow, Fred A.; Nishida,
 Toshiro
 CORPORATE SOURCE: The Burnside Research Laboratory, University of
 Illinois, Urbana, IL, 61801, USA
 SOURCE: Journal of Biological Chemistry (1995), 270(20),
 11812-19
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular
 Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB In the present study, lecithin-cholesterol acyltransferase (LCAT)
 catalyzed esterification of oxysterols was investigated by using diacidol
 bilayer particles (DBP) contg. various oxysterols, phosphatidylcholines,
 and apolipoprotein A-I. The esterified oxysterols were analyzed by high
 pressure liq. chromatog., gas chromatog., and mass spectrometry. LCAT
 esterified all oxysterols tested that are known to be present in human
 plasma. The esterification yields in almost all cases were relatively
 high, often as high as the yield of cholesterol esterification. When DBP
 preps. contg. 27-hydroxycholesterol and various phosphatidylcholines were
 used for the LCAT reaction, both monoesters and diesters were
 produced. The mass spectrometry anal. showed that the monoester was
 produced by the esterification of the 3.beta.-hydroxyl group and not the
 27-hydroxyl group. The diesters were apparently produced by the
 esterification of the 27-hydroxyl group only after the esterification of
 the 3.beta.-hydroxyl group. Phosphatidylcholine contg. a satd. acyl group
 at sn-1 position and an unsatd. acyl group at sn-2 position gave generally
 high esterification yield. The esterification of various oxysterols was
 compared by using DBP contg. dioleoyl-phosphatidylcholine and individual
 oxysterols. All oxysterols produced 3.beta.-oleoyl monoesters. Unlike
 27-hydroxycholesterol, 25-hydroxycholesterol, 7.alpha.-hydroxycholesterol,
 7.beta.-hydroxycholesterol, or cholestanetriol did not produce
 diesters. Various factors influencing the formation of the
 monoesters and diesters from 27-hydroxycholesterol were
 investigated. When dioleoyl-phosphatidylcholine was used as the acyl
 donor, prolonged dialysis of DBP preps. and increase in the ratio of the
 enzyme concn. to substrate particle concn. increased the diester
 formation. Significant amt. of diesters were also produced by
 using 1-palmitoyl-2-oleoylphosphatidylcholine and other
 phosphatidylcholines as the acyl donors. By analyzing the conditions of
 monoester and diester formation, a scheme for the LCAT reaction
 pathway was proposed.

IT 17688-29-8
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (esterification of oxysterols by human plasma lecithin-cholesterol
 acyltransferase to both mono- and di- 3-acyl esters)
 RN 17688-29-8 CAPLUS
 CN 3,5,9-Trioxa-4-phosphanonacos-14,17,20,23-tetraen-1-aminium,
 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(5Z,8Z,11Z,14Z)-1-oxo-5,8,11,14-

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1984:468323 CAPLUS
 DOCUMENT NUMBER: 101:68323
 TITLE: Effects of monolayer lipid structure and composition
 on the lipoprotein lipase-catalyzed hydrolysis of
 triacylglycerol
 AUTHOR(S): Demel, Rudy A.; Dings, Peter J.; Jackson, Richard L.
 CORPORATE SOURCE: Biochem. Lab., State Univ. Utrecht, Utrecht, Neth.
 SOURCE: Biochim. Biophys. Acta (1984), 793(3), 399-407
 CODEN: BBACAQ; ISSN: 0006-3002
 DOCUMENT TYPE: Journal
 LANGUAGE: English



AB The effect of lipid compn. and structure on the lipoprotein lipase
 (I)-catalyzed hydrolysis of triacylglycerols was detd. in a monolayer
 system consisting of purified bovine milk I and fatty acid-free albumin.
 In a monolayer of dioleoylphosphatidylcholine contg. 1-6 mol% of either
 tri[14C]oleoylglycerol or tri[14C]palmitoylglycerol, I catalyzed the
 hydrolysis of triacylglycerol at a higher rate than the satd.
 lipid and in either the presence or absence of apolipoprotein C-II
 (apo-C-II), the activator protein for the enzyme. E.g., with 3 mol%
 triacylglycerol and in the presence of apo-C-II, the rate of the
 I-catalyzed hydrolysis of tri[14C]oleoylglycerol was 27 .mu.mol oleic acid
 produced/h/mg I vs. 12 .mu.mol/h/mg I for tri[14C]palmitoylglycerol. The
 effect of phospholipid fatty acyl chain length and unsatd./satn., polar
 head group and surface d. on the I-catalyzed hydrolysis of
 tri[14C]oleoylglycerol was detd. The rate of I hydrolysis of
 triacylglycerol was similar whether the phospholipid was a diester
 or diether lipid or the polar head group was ethanolamine or choline. In
 general, phospholipids with shorter and unsatd. fatty acyl chains gave
 higher rates of I hydrolysis of triacylglycerol than the corresponding
 longer and satd. lipids. However, with all of the phospholipids tested,
 the rate of I hydrolysis decreased with increasing surface d. I showed no
 activity toward triacylglycerol in a monolayer of sphingomyelin; addn. of
 dioleoylphosphatidylcholine to the monolayer enhanced the rate of I
 catalysis. Cholesterol (50 mol%) in a dipalmitoylphosphatidylcholine
 monolayer increased the rate of the I-catalyzed hydrolysis of
 tri[14C]oleoylglycerol, whereas cholesterol decreased the rate in a
 dioleoylphosphatidylcholine monolayer. The effect of phospholipid
 structure and surface d. on I activity could not be accounted for by the
 amt. of apo-C-II which was present at the interface. Based on these
 findings and other reports in the literature, it is suggested that the
 catalytic activity of I toward tri[14C]oleoylglycerol in various monolayers
 is dependent on the conformation or appropriate phys. state of the
 triacylglycerol substrate at the lipid interface.

IT 14994-07-1 17688-29-8
 RL: BIOL (Biological study)
 (monolayer contg., lipoprotein lipase hydrolysis of triacylglycerols
 in, monolayer structure and compn. effect on)
 RN 14994-07-1 CAPLUS
 CN 5,8,11,14-Eicosatetraenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy
 methyl]-1,2-ethanediy] ester, (5Z,8Z,11Z,14Z)- (9CI) (CA INDEX NAME)



Double bond geometry as shown.

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS (Continued)
 eicosatetraenyl]oxy]-, inner salt, 4-oxide, (7R,14Z,17Z,20Z,23Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.





L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 17688-29-8 CAPLUS
 CN 3,5,9-Trioxa-4-phosphanonacos-14,17,20,23-tetraen-1-aminium,
 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(5Z,8Z,11Z,14Z)-1-oxo-5,8,11,14-
 eicosatetraenyl]oxy]-, inner salt, 4-oxide, (7R,14Z,17Z,20Z,23Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



=> d ibib abs hitstr 114 1-3

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 2001:379313 CAPLUS
 DOCUMENT NUMBER: 135:162209
 TITLE: Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia
 AUTHOR(S): Barber, Matthew D.; Fearon, Kenneth C. H.
 CORPORATE SOURCE: University Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh, EH3 9YW, UK
 SOURCE: Lipids (2001), 36(4), 347-351
 CODEN: LPDASAP; ISSN: 0024-4201
 PUBLISHER: AOCS Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Chemotherapy and radiotherapy offer little benefit to patients with advanced pancreatic cancer. Eicosapentaenoic acid (EPA) has anticancer effects both in vitro and in animal models. The dose of EPA that can be administered to cancer patients has previously been limited by the low purity of available preps. and the tolerability of large capsules. A high-purity prep. of EPA as a 20% oil-in-water diester emulsion allowed a small study of the tolerance, incorporation, and effects of EPA in high doses in five patients with advanced pancreatic cancer. Patients underwent assessment at baseline and every 4 wk thereafter. All patients managed to tolerate a dose providing 18 g EPA per day, with doses between 9 and 27 g daily being taken for at least a month. Dosage was limited by a sensation of fullness, cramping abdominal pain, steatorrhea, and nausea. All such symptoms were controlled by dose redn. or pancreatic enzyme supplements. No other adverse effects attributable to the trial agent were obsd. Plasma phospholipid EPA content increased from around 1% at baseline to 10% at 4 wk and 20% at 8 wk. Incorporation of EPA into red blood cell phospholipids reached levels of around 10%. The present study has shown that a novel, high-purity, EPA diester emulsion can be tolerated at a dose providing around 18 g EPA per day with side-effects being easily controlled. The acceptability of large doses of oral EPA should allow larger controlled clin. studies into potential anticancer effects of EPA.

IT 326798-01-0
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia)

RN 326798-01-0 CAPLUS
 CN 5,8,11,14,17-Eicosapentaenoic acid, 1,3-propanediyl ester, (5Z,5'Z,8Z,8'Z,11Z,11'Z,14Z,14'Z,17Z,17'Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 2000:872177 CAPLUS
 DOCUMENT NUMBER: 134:172777
 TITLE: The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance
 AUTHOR(S): Abulrob, Abdel-Nasser Ghazi; Mason, Malcolm; Bryce, Richard; Gumbleton, Mark
 CORPORATE SOURCE: Pharmaceutical Cell Biology, Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK
 SOURCE: Journal of Drug Targeting (2000), 8(4), 247-256
 CODEN: JDTAEH; ISSN: 1061-186X
 PUBLISHER: Harwood Academic Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Multidrug resistance mediated by overexpression of P-glycoprotein (P-gp) is a major obstacle in the chemotherapeutic management of cancer. The objectives of the current work were to examine if fatty acids affect the intracellular transport and dynamics of doxorubicin in drug-resistant cancer cell lines, and to assess if such effects were mediated through modulation of P-gp efflux pump activity. Among the range of fatty acids tested in this study, eicosapentaenoic acid diester (EPADI) increased doxorubicin accumulation [A] to 137% and retention [R] to 212% in doxorubicin-resistant MCF-7/ADR breast carcinoma cells, and [A] to 147% and [R] to 163% in vinblastine-resistant KBVI nasopharyngeal carcinoma cells. Consistent with EPADI-induced increases in intracellular doxorubicin concns., EPADI (10 .mu.g/mL) sensitized MCF-7/ADR cells to the cytotoxic effects of doxorubicin (1 .mu.g/mL) as assessed by MTT assay (viability < 50% of control), while EPADI itself displayed no cytotoxicity. The combination of EPADI (10 .mu.g/mL) with verapamil (1 .mu.M) resulted in a considerable increase in the [A] and [R] of the model P-gp substrate rhodamine-123 within drug-resistant cells compared to when either agent were used alone. KBVI cells treated with combination of EPADI (10 .mu.g/mL) and verapamil (1 .mu.M) achieved 160% and 1120% greater [A] and [R] of rhodamine-123, resp., compared to untreated cells. The P-gp modulatory effects of EPADI either alone, or as part of a combination with more potent inhibitors, should be further investigated.

IT 326798-01-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effect of fatty acids and analogs upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance)


RN 326798-01-0 CAPLUS
 CN 5,8,11,14,17-Eicosapentaenoic acid, 1,3-propanediyl ester, (5Z,5'Z,8Z,8'Z,11Z,11'Z,14Z,14'Z,17Z,17'Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B




PAGE 1-C



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:176716 CAPLUS

DOCUMENT NUMBER: 132:288942

TITLE: Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat

AUTHOR(S): Schlemmer, C. K.; Coetzer, H.; Claassen, N.; Kruger, M. C.

CORPORATE SOURCE: Department of Physiology, University of Pretoria, Pretoria, 0001, S. Afr.

SOURCE: Prostaglandins, Leukotrienes and Essential Fatty Acids (1999), 61(6), 381-390

CODEN: PLEAEU; ISSN: 0952-3278

PUBLISHER: Churchill Livingstone

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Essential fatty acid deficient animals develop osteoporosis. Eicosapentaenoic acid and gamma-linolenic acid have been reported to have pos. effects on bone metab. in both the growing male rat and the ovariectomized (OVX) female rat. These effects have been further investigated using a novel gamma-linolenic/eicosapentaenoic acid diester together with an estrogen implant in the ovariectomized, female Sprague Dawley rat. Rats were sham-operated or ovariectomized at age 11 wk. Two groups of OVX rats received an estrogen implant at ovariectomy. Animals received fatty acids, linoleic acid (control) or a diester with gamma-linolenic acid and eicosapentaenoic acid as part of a semi-synthetic diet. Bone calcium content and excretion of deoxypyridinolines as marker of bone degradn. were measured at 14 wk. Estrogen, as well as diester alone, increased calcium/femur to sham levels. Estrogen plus diester potentiated the effect of estrogen on bone calcium ($P < 0.05$ vs. OVX). At the same time, estrogen alone and the combination of estrogen plus diester significantly reduced ($P < 0.05$ vs. OVX) urinary deoxypyridinoline and hydroxyproline excretion. Again, the diester potentiated the effect of estrogen. The effects of the diester alone, together with the potentiated effects of estrogen by the essential fatty acids on osteoporosis, are novel findings.

IT 204708-21-4
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (estrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in female Sprague Dawley rat)


RN 204708-21-4 CAPLUS

CN 5,8,11,14,17-Eicosapentaenoic acid, 3-[[[(6Z,9Z,12Z)-1-oxo-6,9,12-octadecatrienyl]oxy]propyl ester, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

37.78

459.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.10

-3.10

STN INTERNATIONAL LOGOFF AT 10:09:07 ON 23 SEP 2002